Document:

Exhibit 4.1

 

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES
REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR (B) AN OPINION OF COUNSEL SELECTED BY THE HOLDER, IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION
IS NOT REQUIRED UNDER SUCH ACT, OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SUCH ACT. NOTWITHSTANDING THE FOREGOING,
THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A FINRA REGISTERED BROKER/DEALER OR OTHER LOAN
OR FINANCING ARRANGEMENT WITH AN “ACCREDITED INVESTOR” SECURED BY THE SECURITIES.

 

MEDICINE MAN TECHNOLOGIES, INC.

Warrant To Purchase Common Stock

 

Warrant No.: LEN-1

Number of Shares of Common Stock: 1,500,000

Date of Issuance: February 26, 2021 (“Issuance
Date”)

 

Medicine Man Technologies,
Inc., a Nevada corporation d/b/a Schwazze (the “Company”), hereby certifies that, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, SHWZ ALTMORE, LLC, the registered holder hereof or its permitted
assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at
the Exercise Price (as defined below) then in effect, at any time or times on or after the date hereof, but not after 11:59 p.m.,
New York time, on the Expiration Date, 1,500,000 fully paid nonassessable shares of Common Stock, all subject to adjustment as
provided herein (the “Warrant Shares” and, together with this Warrant (as defined below), collectively, the
“Securities”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock
(including any Warrants to purchase Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”),
shall have the meanings set forth in Section 14. This Warrant is one of the Warrants to purchase Common Stock (the “Loan
Warrants”) issued pursuant to Section 4.01(b) of the Loan Agreement, dated as of February 26, 2021, by and among the
Company, as guarantor, the borrowers party thereto, the collateral agent, and SHWZ Altmore, LLC, a Delaware limited liability company,
as lender (as amended, the “Loan Agreement”).

 

 

 

 

 

    	 	1	 

     

    

 

 1. EXERCISE OF WARRANT.

 

(a) Mechanics of Exercise.
Subject to the terms and conditions hereof, this Warrant may be exercised by the Holder at any time or times on or after the Issuance
Date, in whole or in part, by (i) delivery of a written notice, in the form attached hereto as Exhibit A (the “Exercise
Notice”), of the Holder’s election to exercise this Warrant and (ii) payment to the Company of an amount equal
to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate
Exercise Price”) in, at the option of the Holder as expressed in the Exericse Notice, either (x) cash by wire transfer
of immediately available funds or (y) payment in accordance with Section 1(e) below. The Holder shall not be required to deliver
the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice with respect to less
than all of the Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant
evidencing the right to purchase the remaining number of Warrant Shares. Execution and delivery of an Exercise Notice for all of
the then-remaining Warrant Shares shall have the same effect as cancellation of the original of this Warrant after delivery of
the Warrant Shares in accordance with the terms hereof. On or before the first Trading Day following the date on which the Company
has received the Exercise Notice, the Company shall transmit by electronic mail an acknowledgment of confirmation of receipt of
the Exercise Notice to the Holder and the Company’s transfer agent (the “Transfer Agent”). On or before
the third Trading Day following the date on which the Company has received the Exercise Notice and the Aggregate Exercise Price,
the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company (“DTC”)
Fast Automated Securities Transfer Program and the Warrant Shares are subject to an effective resale registration statement in
favor of the Holder, credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to
the Holder’s or its designee’s balance account with DTC through its Deposit / Withdrawal At Custodian system, or (Y)
if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program or the Warrant Shares are not
subject to an effective resale registration statement in favor of the Holder, issue and dispatch by overnight courier to the address
as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder
or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise. The Company shall
be responsible for all fees and expenses of the Transfer Agent and all fees and expenses with respect to the issuance of Warrant
Shares via DTC, if any. Upon delivery of the Exercise Notice and the Aggregate Exercise Price, the Holder shall be deemed for all
corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised,
irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates
evidencing such Warrant Shares, as the case may be. If this Warrant is submitted in connection with any exercise pursuant to this
Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of
Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event later than three
Trading Days after any exercise and at its own expense, issue a new Warrant (in accordance with Section 5(d)) representing the
right to purchase the number of Warrant Shares issuable immediately prior to such exercise under this Warrant, less the number
of Warrant Shares with respect to which this Warrant is exercised. No fractional Warrant Shares are to be issued upon the
exercise of this Warrant, but rather the number of Warrant Shares to be issued shall be rounded up to the nearest whole number.
The Company shall pay any and all transfer, stamp, issuance and similar taxes which may be payable with respect to the issuance
and delivery of Warrant Shares upon exercise of this Warrant.

 

(b) Exercise Price.
For purposes of this Warrant, “Exercise Price” means $2.50 per share, subject to adjustment as provided herein.

 

(c) Disputes.
In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the number of Warrant Shares,
the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance
with the terms of this Warrant.

 

 

 

 

    	 	2	 

     

    

 

(d) Insufficient Authorized
Shares. If at any time while this Warrant remains outstanding the Company does not have a sufficient number of authorized and
unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon exercise of this Warrant at least a number
of shares of Common Stock equal to 100% of the number of shares of Common Stock as shall from time to time be necessary to effect
the exercise of all of this Warrant then outstanding (the “Required Reserve Amount” and the failure to have
such sufficient number of authorized and unreserved shares of Common Stock, an “Authorized Share Failure”),
then the Company shall immediately take all action necessary to increase the Company’s authorized shares of Common Stock
to an amount sufficient to allow the Company to reserve the Required Reserve Amount for this Warrant then outstanding. Without
limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share
Failure, but in no event later than 60 days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting
of its stockholders for the approval of an increase in the number of authorized shares of Common Stock. In connection with such
meeting, the Company shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its stockholders’
approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders
that they approve such proposal. Notwithstanding the foregoing, if any such time of an Authorized Share Failure, the Company is
able to obtain the written consent of a majority of the shares of its issued and outstanding shares of Common Stock to approve
the increase in the number of authorized shares of Common Stock, the Company may satisfy this obligation by obtaining such consent
and submitting for filing with the Securities and Exchange Commission an Information Statement on Schedule 14C.

 

(e) Cashless Exercise.
The Holder may elect to pay the Exercise Price by instructing the Company to withhold a number of Warrant Shares then issuable
upon exercise of this Warrant with an aggregate Fair Market Value as of the date of the Exercise Notice equal to the Aggregate
Exercise Price. In the event of any withholding of Warrant Shares pursuant to this Section 1(e) where the number of shares whose
value is equal to the Aggregate Exercise Price is not a whole number, the number of shares withheld by or surrendered to the Company
shall be rounded up to the nearest whole share and the Company shall make a cash payment to the Holder (by delivery of a certified
or official bank check or by wire transfer of immediately available funds) based on the incremental fraction of a share being so
withheld by or surrendered to the Company in an amount equal to the product of (x) such incremental fraction of a share being so
withheld or surrendered multiplied by (y) the Fair Market Value per Warrant Share as of the date of the Exercise Notice.

 

2. ADJUSTMENT OF
EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and the number of Warrant Shares shall be adjusted from time
to time as follows:

 

(a) Voluntary Adjustment
By Company. The Company may at any time during the term of this Warrant, with the prior written consent of the Required Holders,
reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of
the Company.

 

(b) Adjustment Upon
Subdivision or Combination of Common Stock. If the Company at any time on or after the Issuance Date subdivides (by any stock
split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater
number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number
of Warrant Shares will be proportionately increased. If the Company at any time on or after the Issuance Date combines (by combination,
reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares,
the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant
Shares will be proportionately decreased. Any adjustment under this Section 2(b) shall become effective at the close of business
on the date the subdivision or combination becomes effective.

 

 

 

 

    	 	3	 

     

    

 

(c) Adjustment Upon
Reorganization, Reclassification, Consolidation or Merger. In the event of any (i) capital reorganization of the Company, (ii)
reclassification of the stock of the Company (other than a change in par value or from par value to no par value or from no par
value to par value or as a result of a stock dividend or subdivision, split-up or combination of shares), (iii) consolidation or
merger of the Company with or into another Person, (iv) sale of all or substantially all of the Company's assets to another Person
or (v) other similar transaction, in each case which entitles the holders of Common Stock to receive (either directly or upon subsequent
liquidation) stock, securities or assets with respect to or in exchange for Common Stock, each Warrant shall, immediately after
such reorganization, reclassification, consolidation, merger, sale or similar transaction, remain outstanding and shall thereafter,
in lieu of or in addition to (as the case may be) the number of Warrant Shares then exercisable under this Warrant, be exercisable
for the kind and number of shares of stock or other securities or assets of the Company or of the successor Person resulting from
such transaction to which the Holder would have been entitled upon such reorganization, reclassification, consolidation, merger,
sale or similar transaction if the Holder had exercised this Warrant in full immediately prior to the time of such reorganization,
reclassification, consolidation, merger, sale or similar transaction and acquired the applicable number of Warrant Shares then
issuable hereunder as a result of such exercise (without taking into account any limitations or restrictions on the exercisability
of this Warrant); and, in such case, appropriate adjustment (in form and substance satisfactory to the Holder) shall be made with
respect to the Holder’s rights under this Warrant to insure that the provisions of this Section 2 hereof shall thereafter
be applicable, as nearly as possible, to this Warrant in relation to any shares of stock, securities or assets thereafter acquirable
upon exercise of this Warrant (including, in the case of any consolidation, merger, sale or similar transaction in which the successor
or purchasing Person is other than the Company, an immediate adjustment in the Exercise Price to the value per share for the Common
Stock reflected by the terms of such consolidation, merger, sale or similar transaction, and a corresponding immediate adjustment
to the number of Warrant Shares acquirable upon exercise of this Warrant without regard to any limitations or restrictions on exercise,
if the value so reflected is less than the Exercise Price in effect immediately prior to such consolidation, merger, sale or similar
transaction). The provisions of this Section 2(c) shall similarly apply to successive reorganizations, reclassifications, consolidations,
mergers, sales or similar transactions. The Company shall not effect any such reorganization, reclassification, consolidation,
merger, sale or similar transaction unless, prior to the consummation thereof, the successor Person (if other than the Company)
resulting from such reorganization, reclassification, consolidation, merger, sale or similar transaction, shall assume, by written
instrument substantially similar in form and substance to this Warrant and satisfactory to the Holder, the obligation to deliver
to the Holder such shares of stock, securities or assets which, in accordance with the foregoing provisions, such Holder shall
be entitled to receive upon exercise of this Warrant. Notwithstanding anything to the contrary contained herein, with respect to
any corporate event or other transaction contemplated by the provisions of this Section 2(c), the Holder shall have the right to
elect prior to the consummation of such event or transaction, to give effect to the exercise rights contained in Section 1 instead
of giving effect to the provisions contained in this Section 2(c) with respect to this Warrant.

 

3. NONCIRCUMVENTION.
The Company hereby covenants and agrees that the Company will not, by amendment of its Articles of Incorporation or Bylaws, or
through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities,
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will
at all times in good faith carry out all of the provisions of this Warrant and take all action as may be required to protect the
rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any
shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all
such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable
shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the Loan Warrants are outstanding,
take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the
purpose of effecting the exercise of the Loan Warrants, 100% of the number of shares of Common Stock as shall from time to time
be necessary to effect the exercise of the Loan Warrants then outstanding.

 

 

 

 

 

    	 	4	 

     

    

 

4. WARRANT HOLDER
NOT DEEMED A STOCKHOLDER. The Holder, solely in its capacity as a holder of this Warrant, shall not be entitled to vote or
receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this
Warrant be construed to confer upon the Holder, solely in its capacity as the Holder of this Warrant, any of the rights of a stockholder
of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock,
reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription
rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which it is then entitled to receive upon the due
exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the
Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company.

 

5. REISSUANCE OF
WARRANTS.

 

(a) Transfer of Warrant.
If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith
issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 5(d)), registered as the Holder may request,
representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number
of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 5(d)) to the Holder
representing the right to purchase the number of Warrant Shares not being transferred.

 

(b) Lost, Stolen or
Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder
to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall
execute and deliver to the Holder a new Warrant (in accordance with Section 5(d)) representing the right to purchase the Warrant
Shares then underlying this Warrant.

 

(c) Exchangeable for
Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company,
for a new Warrant or Warrants (in accordance with Section 5(d)) representing in the aggregate the right to purchase the number
of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of
such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no Loan
Warrants for fractional Warrant Shares shall be given.

 

(d) Issuance of New
Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i)
shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase
the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 5(a) or Section
5(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other
new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant),
(iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv)
shall have the same rights, terms and conditions as this Warrant.

 

6. REPRESENTATIONS
AND WARRANTIES OF THE HOLDER. As of the Issuance Date and upon delivery of each Exercise Notice, the Holder represents and
warrants to the Company as follows:

 

(a) No Public Sale
or Distribution. The Holder is acquiring this Warrant, and when issued in accordance with the terms of this Warrant, the Warrant
Shares, in the ordinary course of its business for its own account and not with a view towards, or for resale in connection with,
the public sale or distribution thereof, except pursuant to sales registered or exempted under the Securities Act of 1933, as amended
(the “Securities Act”). The Holder does not presently have any agreement or understanding, directly or indirectly,
with any Person to distribute any of the Securities.

 

 

 

 

    	 	5	 

     

    

 

(b) Holder Status
and Experience. The Holder is, and on each date on which the Holder acquires any Warrant Shares it will be, an “accredited
investor” as that term is defined in Rule 501(a) of Regulation D. The Holder, either alone or together with its representatives,
has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits
and risks of the investment in the Securities, and has so evaluated the merits and risks of such investment. The Holder is able
to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such
investment.

 

(c) Information.
The Holder and its advisors, if any, have been furnished with all materials relating to the business finances and operations of
the Company and materials relating to the offer and issuance of the Securities that have been requested by the Holder. The Holder
and its advisors, if any, have been afforded the opportunity to ask questions of the Company and receive answers from the Company
concerning the terms and conditions of the offering of the Securities, the merits of investing in the Securities and the business,
finances and operations of the Company. Neither such inquiries nor any other due diligence investigations conducted by the Holder
or is advisors, if any, or its representatives shall modify, amend or affect the Holder’s right to rely on the Company’s
representations and warranties contained herein. The Holder understands that its investment in the Securities involves a high degree
of risk. The Holder has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment
decision with respect to its acquisition of the Securities.

 

(d) Transfer or Resale.
The Holder understands that: (i) the Securities are “restricted securities” under applicable securities laws and have
not been and are not being registered under the Securities Act or any state securities laws, and may not be offered for sale, sold,
assigned or transferred unless (A) subsequently registered thereunder, (B) the Holder shall have delivered to the Company (if requested
by the Company) an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Securities to be
sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) the
Holder provides the Company with reasonable assurance that such Securities can be sold, assigned or transferred pursuant to Rule
144 or Rule 144A promulgated under the Securities Act (or a successor rule thereto) (collectively, “Rule 144”);
(ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and further,
if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom
the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with
some other exemption under the Securities Act or the rules and regulations of the Securities and Exchange Commission thereunder;
and (iii) neither the Company nor any other Person is under any obligation to register the Securities under the Securities Act
or any state securities laws or to assist the Holder to comply with the terms and conditions of any exemption thereunder. Notwithstanding
the foregoing, the Securities may be pledged in connection with a bona fide margin account with a FINRA registered broker/dealer
or other loan or financing arrangement with an accredited investor secured by the Securities and such pledge of Securities shall
not be deemed to be a transfer, sale or assignment of the Securities hereunder, and if the Holder effects such a pledge of Securities
it shall not be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant
to this Agreement. The Holder understands that the Warrant Shares shall bear such restrictive legend as required by the Company.
THE HOLDER UNDERSTANDS THAT THE WARRANT SHARES WILL BE SUBJECT TO THE TERMS AND PROVISIONS OF (A) THE ARTICLES OF INCORPORATION
OF THE COMPANY, AS AMENDED FROM TIME TO TIME, INCLUDING, WITHOUT LIMITATION, THE CERTIFICATES OF DESIGNATION RELATING TO ALL SERIES
OF PREFERRED STOCK, AND THE RELATIVE RIGHTS, PREFERENCES, RESTRICTIONS, DESIGNATIONS, QUALIFICATIONS AND PRIVILEGES SET FORTH THEREIN
AND IMPOSED THEREON AND UPON THE HOLDERS THEREOF, AND (B) THE BYLAWS OF THE COMPANY, AS AMENDED FROM TIME TO TIME, INCLUDING, WITHOUT
LIMITATION, A REDEMPTION RIGHT IN FAVOR OF THE COMPANY, TO ALL OF WHICH TERMS AND PROVISIONS THE HOLDER, BY ACCEPTANCE HEREOF,
ASSENTS.

 

(e) Reliance on Exemptions.
The Holder understands that the Securities are being offered and issued to it in reliance on specific exemptions from the registration
requirements of applicable securities laws and that the Company is relying in part upon the truth and accuracy of, and the Holder’s
compliance with, the representations and warranties of the Holder set forth herein in order to determine the availability of such
exemptions and eligibility of the Holder to acquire the Securities.

 

 

 

 

    	 	6	 

     

    

 

(f) Bad Actor.
Neither the Holder, nor any of its directors, executive officers, general partners, managers, managing members or beneficial owners
of 20% of the Holder’s outstanding voting equity securities, calculated on the basis of voting power, is subject to any “Bad
Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) promulgated under the Securities Act (a “Disqualification
Event”), except for a Disqualification Event (i) contemplated by Rule 506(d)(2) promulgated under the Securities Act,
and (ii) a description of which has been furnished in writing to the Company before the date hereof.

 

(g) FINRA Lists.
The Holder is not included in the list of entities barred by the Financial Industry Regulatory Authority.

 

(h) Blocked Persons
and Sanctions. Neither the Holder nor any director, officer, employee, agent, affiliate or other Person associated with or
acting on behalf of the Holder is, or is directly or indirectly owned or controlled by, a Person that is restricted from doing
business under the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism
Act of 2001, H.R. 3162, Public Law 107-56, as amended (commonly known as the “USA Patriot Act”), or any executive order,
including, without limitation, Executive Order Number 13224 on Terrorism Financing, effective September 24, 2001, and the regulations
promulgated pursuant thereto or currently the subject or the target of any sanctions administered or enforced, or any relevant
lists maintained, by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department
of the Treasury or the U.S. Departments of State or Commerce and including, without limitation, the designation as a “Specially
Designated National” or on the “Sectoral Sanctions Identifications List”, collectively “Blocked Persons”),
the United Nations, the European Union, Her Majesty’s Treasury, the North Atlantic Treaty Organization, the Financial Action
Task Force on Money Laundering of Organization for Economic Cooperation and Development, or any other relevant sanctions authority
(collectively, “Sanctions Laws”); neither the Holder, nor any director, officer, employee, agent, affiliate
or other Person associated with or acting on behalf of the Holder is located, organized or resident in a country or territory that
is the subject or target of a comprehensive embargo or Sanctions Laws prohibiting trade with the country or territory, including,
without limitation, Crimea, Cuba, Iran, North Korea, Sudan and Syria (each, a “Sanctioned Country”); neither
the Holder nor any director, officer, employee, agent, affiliate or other Person associated with or acting on behalf of the Holder,
acting in any capacity in connection with the operations of the Holder, conducts any business with or for the benefit of any Blocked
Person or engages in making or receiving any contribution of funds, goods or services to, from or for the benefit of any Blocked
Person, or deals in, or otherwise engages in any transaction relating to, any property or interests in property blocked or subject
to blocking pursuant to any applicable Sanctions Laws. The Holder has not knowingly engaged in and is not now knowingly engaged
in any dealings or transactions with any Person that at the time of the dealing or transaction is or was the subject or the target
of Sanctions Laws or with any Sanctioned Country.

 

(i) Foreign
Political Figure. Neither the Holder nor any of its directors, executive officers, general partners, managers, managing members
or beneficial owners is a senior foreign political figure, any member of a senior foreign political figure’s immediate family
or any close associate of a senior foreign political figure.

 

7. NOTICES.

 

(a) Whenever
notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance with
Section 9.01 of the Loan Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant
to this Warrant, including in reasonable detail a description of such action and the reason therefor. Without limiting the generality
of the foregoing, the Company will give written notice to the Holder immediately upon any adjustment of the Exercise Price, setting
forth in reasonable detail, and certifying, the calculation of such adjustment.

 

(b) In
the event:

 

(i)that the Company
shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon exercise
of the Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution, to vote at a meeting
(or by written consent), to receive any right to subscribe for or purchase any shares of capital stock of any class or any other
securities, or to receive any other security; or

 

 

 

 

    	 	7	 

     

    

 

 

(ii)of any capital
reorganization of the Company, any reclassification of the Common Stock of the Company, any consolidation or merger of the Company
with or into another Person, or sale of all or substantially all of the Company's assets to another Person; or

 

(iii)of the voluntary
or involuntary dissolution, liquidation or winding-up of the Company;

 

then, and in each such
case, the Company shall send or cause to be sent to the Holder at least 20 Business Days prior to the applicable record date or
the applicable expected effective date, as the case may be, for the event, a written notice specifying, as the case may be, (A)
the record date for such dividend, distribution, meeting or consent or other right or action, and a description of such dividend,
distribution or other right or action to be taken at such meeting or by written consent, or (B) the effective date on which such
reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding-up is proposed to take place,
and the date, if any is to be fixed, as of which the books of the Company shall close or a record shall be taken with respect to
which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon exercise of the
Warrant) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities
or other property deliverable upon such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation
or winding-up, and the amount per share and character of such exchange applicable to the Warrant and the Warrant Shares.

 

8. AMENDMENT AND
WAIVER. Except as otherwise provided herein, the provisions of this Warrant and the other Loan Warrants may be amended or waived
and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if
the Company has obtained the written consent of the Required Holders and any amendment, waiver or action made in conformity with
the provisions of this Section 8 shall be binding on all holders of Loan Warrants and the Company. The Holder acknowledges and
agrees that by operation of this Section 8, the Required Holders will have the right and power to amend this Warrant and the other
Loan Warrants, including, without limitation, the power to diminish or eliminate all rights of the Holder under this Warrant.

 

9. GOVERNING LAW;
JURISDICTION; JURY TRIAL. This Warrant shall be governed by and construed and enforced in accordance with, and all questions
concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of
the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of
New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of
New York. The Company and the Holder each hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and each hereby irrevocably waives, and agrees not to assert in
any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. The
Company and the Holder each hereby irrevocably waives personal service of process and consents to process being served in any such
suit, action or proceeding by mailing a copy thereof to the respective address set forth in Section 9.01 of the Loan Agreement
or otherwise designated in writing pursuant to Section 9.01 of the Loan Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any manner permitted by law. THE COMPANY AND THE HOLDER EACH HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE,
AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS
WARRANT.

 

10. CONSTRUCTION;
HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against
any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or
affect the interpretation of, this Warrant.

 

 

 

 

    	 	8	 

     

    

 

11. REMEDIES, OTHER
OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in addition to all
other remedies available under this Warrant and the other Loan Documents (as defined in the Loan Agreement), at law or in equity
(including, without limitation, a decree of specific performance and/or other injunctive relief), and nothing herein shall limit
the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company
acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at
law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach, the holder of this
Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach.

 

12. TRANSFER.
This Warrant and the Warrant Shares may be offered for sale, sold, transferred, pledged or assigned without the consent of the
Company, subject to compliance with all applicable federal and state securities laws.

 

13. SEVERABILITY.
If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect
the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without material
change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability
of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties
or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good
faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which
comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

14. CERTAIN DEFINITIONS.
For purposes of this Warrant, the following terms shall have the following meanings:

 

(a) “Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed.

 

(b) “Common
Stock” means (i) the Company’s shares of common stock, par value $0.001 per share, and (ii) any stock capital into
which such Common Stock shall have been changed or any stock capital resulting from a reclassification, reorganization or reclassification
of such Common Stock.

 

(c) “Expiration
Date” means the date 60 months after the Issuance Date or, if such date falls on a day other than a Business Day or a
Trading Day (such day, a “Holiday”), the next day that is not a Holiday.

 

(d) “Fair Market
Value” means, as of any particular date, the arithmetic average over the 20 consecutive Trading Days ending on the Trading
Day immediately prior to the day as of which “Fair Market Value” is being determined of, as applicable, (i) the volume
weighted average of the closing sales prices of the Common Stock for such day on all domestic securities exchanges on which the
Common Stock may at the time be listed; (ii) if there have been no sales of the Common Stock on any such exchange on any such
day, the average of the highest bid and lowest asked prices for the Common Stock on all such exchanges at the end of such day;
(iii) if on any such day the Common Stock is not listed on a domestic securities exchange, the closing sales price of the Common
Stock as quoted on the Principal Market; or (iv) if there have been no sales of the Common Stock on Principal Market on any such
day, the average of the highest bid and lowest asked prices for the Common Stock quoted on the Princial Market at the end of such
day. If at any time the Common Stock is not listed on any domestic securities exchange or quoted on the Principal Market or similar
quotation system or association, the “Fair Market Value” of the Common Stock shall be the fair market value per share
as determined jointly by the Company and the Holder; provided, that if the Company and the Holder are unable to agree on
the fair market value per share of the Common Stock within a reasonable period of time (not to exceed 20 days from the Company’s
receipt of the Exercise Notice), such fair market value shall be determined by a nationally recognized investment banking, accounting
or valuation firm jointly selected by the Company and the Holder. The determination of such firm shall be final and conclusive,
and the fees and expenses of such firm shall be borne by the Company. All such determinations shall be appropriately adjusted
for any stock dividend, stock split, stock combination, reclassification or other similar transaction during the applicable calculation
period.

 

 

 

 

    	 	9	 

     

    

 

(e) “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and a government or any department or agency thereof.

 

(f) “Principal
Market” means the OTCQX.

 

(g) “Required
Holders” means the holders of the Loan Warrants representing at least a majority of the shares of Common Stock underlying
all of the Loan Warrants then outstanding.

 

(h) “Trading
Day” means any day on which the Common Stock is traded or qualified for quotation on the Principal Market, or, if the
Principal Market is not the principal trading market for the Common Stock on such day, then on the principal securities exchange
or securities market on which the Common Stock is then traded or qualified for quotation.

 

[Signature Page Follows]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	10	 

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.

 

	 	
         

        

        

        MEDICINE MAN TECHNOLOGIES, INC.

         

        By: /s/ Justin Dye                                                         

        Name: Jusin Dye

        Title: Chief Executive Officer

         

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	11	 

     

    

 

EXHIBIT A

 

FORM OF EXERCISE NOTICE

TO BE EXECUTED BY THE REGISTERED HOLDER
TO EXERCISE THIS

WARRANT TO PURCHASE COMMON STOCK

MEDICINE MAN TECHNOLOGIES, INC.

 

The undersigned holder
hereby exercises the right to purchase ____________ shares of Common Stock (“Warrant Shares”) of Medicine Man
Technologies, Inc., a Nevada corporation d/b/a/ Schwazze (the “Company”), evidenced by the attached Warrant
to Purchase Common Stock (the “Warrant”). Capitalized terms used herein and not otherwise defined shall have
the respective meanings set forth in the Warrant.

 

1. Payment of Exercise
Price. The holder shall pay the Aggregate Exercise Price in the sum of $__________________ to the Company in accordance with
the terms of the Warrant. Payment is to be paid [ ] in cash or [ ] pursuant to Section 1(e) of the Warrant.

 

2. Delivery of Warrant
Shares. The Company shall deliver to the holder ____________ Warrant Shares in accordance with the terms of the Warrant.

 

3. Representations
and Warranties. The representations and warranties set forth in Section 6 of the Warrant are true and correct in all respects
with the same effect as though such representations and warranties had been made as of the date of this Exercise Notice.

 

Please issue the Warrant Shares in the
following name and to the following account:

 

	Issue to:	 
	 	 
	 	 

 

	Facsimile Number and Electronic Mail:	 
	 	 
	Authorization:	 
	 	 
	By:	 
	 	 
	Title:	 
	 	 
	Dated:	 
	 	 
	Broker Name:	 
	 	 
	Broker DTC #:	 
	 	 
	Broker Telephone #:	 
	 	 
	Account Number:	 
	  (if electronic book entry transfer)	 
	 	 
	Transaction Code Number:	 
	  (if electronic book entry transfer)	 

 

 

 

 

 

    	 	12	 

     

    

 

ACKNOWLEDGMENT

 

The Company hereby acknowledges this Exercise
Notice and hereby directs the Transfer Agent to issue the above indicated number of shares of Common Stock.

 

	 	
         

        

        

        MEDICINE MAN TECHNOLOGIES, INC.

         

        By: _________________________

               Name:

               Title:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	13Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

 

SECURITIES PURCHASE
AGREEMENT (this “Agreement”), dated as of February 26, 2021 by and between Medicine Man Technologies, Inc.
a Nevada corporation (the “Company”), and CRW Capital Cann Holdings, LLC, a Delaware limited liability company
(the “Buyer”).

 

WHEREAS:

 

A.       The
Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Rule 506(b) of Regulation
D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the 1933 Act.

 

B.       The
Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, an aggregate
of up to 30,000 shares (such shares issued at each Closing (as defined below) hereunder are referred to herein as the “Shares”)
of the Company’s Series A preferred stock, par value $0.001 per share (the “Preferred Stock”), having
the rights, preferences and privileges set forth in the Certificate of Designation filed with the Nevada Secretary of State on
December 16, 2020 (the “Certificate of Designation”), including the conversion of such Preferred Stock into
shares of the Company’s common stock, par value $0.001 per share (“Common Stock”). Such purchase and sale
of Preferred Stock shall take place in one or more closings (each applicable closing, the “Closing”), subject
to the terms and conditions of this Agreement, provided that no Closing shall take place after March 5, 2021 without the mutual
written agreement of the Buyer and the Company.

 

C.       (i)
The Shares and (ii) the shares of Common Stock issued and issuable upon conversion of the Shares in accordance with the terms of
the Certificate of Designation (collectively, the “Underlying Shares”), are collectively referred to herein
as the “Securities.”

 

NOW, THEREFORE,
the Company and the Buyer hereby agree as follows:

 

1.                 
PURCHASE AND SALE OF SHARES.

 

(a)              
Purchase of Shares. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 5
and 6 below at each Closing, the Company shall issue and sell to the Buyer and the Buyer agrees to purchase from the Company
at each Closing the number of Shares determined upon mutual written agreement of the Buyer and the Company (up to an aggregate
of 30,000 Shares).

 

(b)              
Closing. The date of each Closing shall be on such date and time as is mutually agreed to by the Company and the
Buyer after notification of satisfaction (or waiver) of the conditions to such Closing set forth in Sections 5 and
6 below, and each Closing shall be undertaken remotely by electronic transfer of Closing documentation.

 

(c)              
Purchase Price. The purchase price for the Shares to be purchased by the Buyer at each Closing shall be $1,000 per
Share (the “Purchase Price”).

 

(d)              
Form of Payment. On or before each Closing, (i) the Buyer shall pay the aggregate Purchase Price to the Company for
the Shares to be issued and sold to the Buyer at such Closing by wire transfer of immediately available funds in accordance with
the Company’s written wire instructions; and (ii) the Company shall deliver to the Buyer one or more stock certificates,
evidencing the number of Shares the Buyer is purchasing at such Closing, duly executed on behalf of the Company and registered
in the name of the Buyer.

 

 

 

 

    	 	1	 

     

    

 

2.                 
BUYER’S REPRESENTATIONS AND WARRANTIES. The Buyer represents and warrants to the Company that, as of the date
hereof and as of each Closing (unless as of a specific date therein, in which case they shall be accurate as of such date):

 

(a)              
No Public Sale or Distribution. The Buyer is (i) acquiring the Shares, and (ii) when issued in accordance with
the terms of the Certificate of Designation, will acquire the Underlying Shares, in the ordinary course of its business for its
own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant
to sales registered or exempted under the 1933 Act; provided, however, that by making the representations herein, except as otherwise
set forth herein or the other Transaction Documents (as defined in Section 3(b)), the Buyer does not agree to hold
any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in
accordance with or pursuant to a registration statement or an exemption under the 1933 Act. The Buyer does not presently have any
agreement or understanding, directly or indirectly, with any Person to distribute any of the Securities. As used herein, “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and any governmental entity or any department or agency thereof.

 

(b)              
Buyer Status and Experience. The Buyer is, and on each date on which the Buyer acquires any Underlying Shares it
will be, an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (“Accredited Investor”).
The Buyer, either alone or together with its representatives, has such knowledge, sophistication and experience in business and
financial matters so as to be capable of evaluating the merits and risks of the investment in the Securities, and has so evaluated
the merits and risks of such investment. The Buyer is able to bear the economic risk of an investment in the Securities and, at
the present time, is able to afford a complete loss of such investment.

 

(c)              
Reliance on Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance on
specific exemptions from the registration requirements of the United States federal and state securities laws and that the Company
is relying in part upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and
the eligibility of the Buyer to acquire the Securities.

 

(d)              
Information. The Buyer and its advisors, if any, have been furnished with a copy of the Company’s Confidential
Private Placement Memorandum, dated November 6, 2020, the Company’s Supplement No. 1 to Confidential Private Placement Memorandum,
dated February 2, 2021 and the Company’s Supplement No. 2 to Confidential Private Placement Memorandum, dated February 24,
2021 (collectively, the “Confidential PPM”). The Buyer has had access to such information and materials relating
to the business, finances and operations of the Company, including the terms of the Proposed Transaction (as defined below), that
have been requested by the Buyer and to the satisfaction of the Buyer. The Buyer and its advisors, if any, have been afforded the
opportunity to ask questions of the Company and receive answers from the Company concerning the terms and conditions of the offering
of the Securities, the merits and risks of investing in the Securities and the business, finances and operations of the Company
to the satisfaction of the Buyer. Neither such inquiries nor any other due diligence investigations conducted by the Buyer or its
advisors, if any, or its representatives shall modify, amend or affect the Buyer’s right to rely on the Company’s representations
and warranties contained herein. The Buyer understands that its investment in the Securities involves a high degree of risk, including
the risks outlined in the Confidential PPM. The Buyer has sought such accounting, legal and tax advice as it has considered necessary
to make an informed investment decision with respect to its acquisition of the Securities.

 

(e)              
No Governmental Review. The Buyer understands that no United States federal or state agency or any other
government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or
suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of
the Securities.

 

 

 

 

    	 	2	 

     

    

 

(f)               
Transfer or Resale. The Buyer understands that: (i) the Securities have not been and are not being registered under
the 1933 Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently
registered thereunder, (B) the Buyer shall have delivered to the Company (if requested by the Company) an opinion of counsel, in
a form reasonably acceptable to the Company, to the effect that such Securities to be sold, assigned or transferred may be sold,
assigned or transferred pursuant to an exemption from such registration, or (C) the Buyer provides the Company with reasonable
assurance that such Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the
1933 Act, as amended, (or a successor rule thereto) (collectively, “Rule 144”); (ii) any sale of the Securities
made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and further, if Rule 144 is not applicable,
any resale of the Securities under circumstances in which the seller (or the Person through whom the sale is made) may be deemed
to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933
Act or the rules and regulations of the SEC thereunder; and (iii) except as otherwise provided herein, neither the Company nor
any other Person is under any obligation to register the Securities under the 1933 Act or any state securities laws or to comply
with the terms and conditions of any exemption thereunder. Notwithstanding the foregoing, the Securities may be pledged in connection
with a bona fide margin account with a FINRA registered broker/dealer or other loan or financing arrangement with an Accredited
Investor secured by the Securities and such pledge of Securities shall not be deemed to be a transfer, sale or assignment of the
Securities hereunder, and if the Buyer effects such a pledge of Securities it shall not be required to provide the Company with
any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document,
including, without limitation, this Section 2(f).

 

(g)              
Legends. The Buyer understands that the Securities are “restricted securities” under applicable federal
and state securities laws and that certificates or other instruments representing Securities except as set forth below, shall bear
a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of such Securities):

 

[NEITHER THE
ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE
HAVE BEEN] [THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE
OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF
COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED
UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE
FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A FINRA REGISTERED BROKER/DEALER OR
OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

THE SECURITIES
REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND PROVISIONS OF (A) THE ARTICLES OF INCORPORATION OF THE CORPORATION,
AS AMENDED FROM TIME TO TIME, INCLUDING, WITHOUT LIMITATION, THE CERTIFICATES OF DESIGNATION RELATING TO ALL SERIES OF PREFERRED
STOCK, AND THE RELATIVE RIGHTS, PREFERENCES, RESTRICTIONS, DESIGNATIONS, QUALIFICATIONS AND PRIVILEGES SET FORTH THEREIN AND IMPOSED
THEREON AND UPON THE HOLDERS THEREOF, AND (B) THE BYLAWS OF THE CORPORATION, AS AMENDED FROM TIME TO TIME, TO ALL OF WHICH TERMS
AND PROVISIONS THE HOLDER OF THIS CERTIFICATE, BY ACCEPTANCE HEREOF, ASSENTS.

 

 

 

 

    	 	3	 

     

    

 

THE SECURITIES
REPRESENTED BY THIS CERTIFICATE [AND THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE] ARE SUBJECT TO THE TERMS AND CONDITIONS
OF A LOCK-UP PROVISION IN THE SECURITIES PURCHASE AGREEMENT AND/OR SUBSCRIPTION AGREEMENT BETWEEN THE CORPORATION AND THE STOCKHOLDER
LISTED ON THE FACE HEREOF, AS AMENDED FROM TIME TO TIME. SUCH LOCK-UP PROVISION INCLUDES CONDITIONS AND OTHER RESTRICTIONS UPON
THE TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE [AND THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE],
INCLUDING, WITHOUT LIMITATION, AFFIRMATIVE STEPS REQUIRED TO BE UNDERTAKEN BY ANY POTENTIAL TRANSFEREE OF THE SECURITIES REPRESENTED
BY THIS CERTIFICATE AS A CONDITION TO SUCH TRANSFER. ANY PURPORTED TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE [AND
THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE] IN VIOLATION OF SUCH LOCK-UP PROVISION IS VOID AB INITIO.

 

COPIES OF SUCH
DOCUMENTS ARE ON FILE AT THE PRINCIPAL OFFICE OF THE CORPORATION AND ARE MADE A PART HEREOF AS THOUGH FULLY SET FORTH ON THIS CERTIFICATE.”

 

No later than two days on which the principal
Trading Market (as defined below) is open (“Trading Days”) following the delivery by the Buyer to the Company
or its transfer agent of a certificate representing Securities issued with a restrictive legend (such date, the “Legend
Removal Date”), such legend shall be removed and the Company shall issue a certificate without such legend to the Buyer
or issue to the Buyer such Securities by electronic delivery at the applicable balance account at The Depository Trust Company
(“DTC”), if such Securities are DTC-eligible at such time, if (i) such Securities are registered for resale
under the 1933 Act and the holder has provided the Company with such documents as are reasonably required by the Company in connection
with the removal of the legend, including but not limited to the Buyer’s representation letter indicating an intent to sell,
(ii) in connection with a sale, assignment or other transfer, such holder provides the Company with an opinion of counsel, in a
generally acceptable form, to the effect that such sale, assignment or transfer of the Securities may be made without registration
under the applicable requirements of the 1933 Act, (iii) the Securities can be sold, assigned or transferred pursuant to Rule 144
without restriction or limitation, including without the requirement to be in compliance with Rule 144(c)(1), or Rule 144A, or
(iv) if such legend is not required under applicable requirements of the 1933 Act (including, without limitation, controlling judicial
interpretations and pronouncements issued by the SEC). The Company shall be responsible for the fees of its transfer agent and
all DTC fees associated with such issuance. If the Company shall fail for any reason or for no reason to issue to the Buyer,
a certificate without such legend to such holder or to issue to the Buyer such Securities by electronic delivery at the applicable
balance account at DTC, if such Securities are DTC-eligible at such time, on or before the applicable Legend Removal Date, and
if after such Legend Removal Date the Buyer purchases (in an open market transaction or otherwise) Securities to deliver in satisfaction
of a sale by the Buyer of all or any portion of the Securities that the holder anticipated receiving without legend from the Company,
then the Company shall, within five Trading Days after the Buyer’s request and in the Buyer’s discretion, either (i)
pay cash to the Buyer in an amount equal to the Buyer’s total purchase price (including brokerage commissions, if any) for
the Securities so purchased (the “Buy-In Price”), at which point the Company’s obligation to deliver such
unlegended Securities shall terminate, or (ii) promptly honor its obligation to deliver to the Buyer such unlegended Securities
as provided above and pay cash to the Buyer in an amount equal to the excess (if any) of the Buy-In Price over the product of (A)
such number Securities, times (B) any trading price of the Securities selected by the Buyer in writing as in effect at any time
during the period beginning on the applicable Legend Removal Date and the date the Company makes the applicable cash payment. The
Company acknowledges that a breach by it of its obligations under this Section 2(g) will cause irreparable harm to the Buyer.
Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section 2(g) will
be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section 2(g),
that the Buyer shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach
and requiring immediate issuance and transfer, without the necessity of showing economic loss and without any bond or other security
being required.

 

 

 

 

    	 	4	 

     

    

 

(h)              
Validity; Enforcement. The Buyer is either an individual or an entity duly incorporated or formed, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership,
limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction
Documents and otherwise to carry out its obligations hereunder and thereunder. This Agreement and each other Transaction Document
have been duly and validly authorized, executed and delivered on behalf of the Buyer and constitutes the legal, valid and binding
obligations of the Buyer enforceable against the Buyer in accordance with their respective terms, except as such enforceability
may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation
and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(i)                
No Conflicts. The execution, delivery and performance by the Buyer of this Agreement and each other Transaction
Document and the consummation by the Buyer of the transactions contemplated hereby and thereby will not (i) result in a violation
of the organizational documents of the Buyer or (ii) conflict with, or constitute a default (or an event which with notice or lapse
of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which the Buyer is a party, or (iii) result in a violation of any law, rule, regulation,
order, judgment or decree (including federal and state securities laws) applicable to the Buyer, except in the case of clauses
(ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably
be expected to have a material adverse effect on the ability of the Buyer to perform its obligations hereunder.

 

(j)                
Residency. The Buyer is a resident of the jurisdiction specified on the signature page attached hereto.

 

(k)              
No Conflicts with Sanctions Laws. Neither the Buyer nor any director, officer, employee, agent, affiliate or
other person associated with or acting on behalf of the Buyer is, or is directly or indirectly owned or controlled by, a Person
that is currently the subject or the target of any sanctions administered or enforced by the U.S. government (including, without
limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Departments of State or Commerce
and including, without limitation, the designation as a “Specially Designated National” or on the “Sectoral Sanctions
Identifications List”, collectively “Blocked Persons”), the United Nations Security Council, the European
Union, Her Majesty’s Treasury or any other relevant sanctions authority (collectively, “Sanctions Laws”);
neither the Buyer, nor any director, officer, employee, agent, affiliate or other person associated with or acting on behalf of
the Buyer is located, organized or resident in a country or territory that is the subject or target of a comprehensive embargo
or Sanctions Laws prohibiting trade with the country or territory, including, without limitation, Crimea, Cuba, Iran, North Korea,
Sudan and Syria (each, a “Sanctioned Country”); neither the Buyer nor any director, officer, employee, agent,
affiliate or other person associated with or acting on behalf of the Buyer, acting in any capacity in connection with the operations
of the Buyer, conducts any business with or for the benefit of any Blocked Person or engages in making or receiving any contribution
of funds, goods or services to, from or for the benefit of any Blocked Person, or deals in, or otherwise engages in any transaction
relating to, any property or interests in property blocked or subject to blocking pursuant to any applicable Sanctions Laws. No action
of the Buyer in connection with the execution, delivery and performance of this Agreement and the other Transaction Documents or
the consummation of any other transaction contemplated hereby or by the other Transaction Documents or the fulfillment of the terms
hereof or thereof. For the past five years, the Buyer has not knowingly engaged in and is not now knowingly engaged in any dealings
or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions
Laws or with any Sanctioned Country.

 

3.                 
REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

 

 

 

    	 	5	 

     

    

 

The Company represents
and warrants to the Buyer that, as of the date hereof and as of each Closing:

 

(a)              
Organization and Qualification. The Company and each of its “Subsidiaries” (which for purposes
of this Agreement means any entity in which the Company, directly or indirectly, owns any of the capital stock or holds an equity
or similar interest), if any, are entities duly organized and validly existing and in good standing under the laws of the jurisdiction
in which they are formed, and have the requisite power and authorization to own their properties and to carry on their business
as now being conducted and as presently proposed to be conducted. Each of the Company and each of its Subsidiaries is duly qualified
as a foreign entity to do business and is in good standing in every jurisdiction in which its ownership of property or the nature
of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or
be in good standing would not reasonably be expected to have a Material Adverse Effect. As used in this Agreement, “Material
Adverse Effect” means any fact, occurrence, circumstance, event or change that, individually or in the aggregate, has
had, or would reasonably be expected to have, a material adverse effect on the business, properties, assets, liabilities, operations,
results of operations, or condition (financial or otherwise) of the Company and its Subsidiaries taken as a whole, or on the transactions
contemplated hereby or on the other Transaction Documents or by the agreements and instruments to be entered into in connection
herewith or therewith, or on the authority or ability of the Company to perform any of its obligations under any of the Transaction
Documents, except to the extent related to: (i) a change in general political, economic, or financial market conditions (except
if such conditions have had, or would reasonably be expected to have, a disproportionately adverse effect on the Company and its
Subsidiaries, taken as a whole, relative to other Persons operating in the industries in which the Company or its Subsidiaries
operate generally); (ii) a change that affected the industries in which the Company or its Subsidiaries operate generally (except
if such change has had, or would reasonably be expected to have, a disproportionately adverse effect on the Company or its Subsidiaries,
taken as a whole, relative to other Persons operating in the industries in which the Company or its Subsidiaries operate generally);
(iii) the announcement or pendency of this Agreement and the transactions contemplated hereby; (iv) any changes after the date
of this Agreement in GAAP or Applicable Law or the enforcement, implementation or interpretation thereof (except if such changes
have had, or would reasonably be expected to have, a disproportionately adverse effect on the Company or its Subsidiaries, taken
as a whole, relative to other Persons operating in the industries in which the Company or its Subsidiaries operate generally);
(v) natural disaster, sabotage, acts of terrorism, civil unrest, rioting, looting or war (whether or not declared) or other outbreak
of hostilities or escalation thereof; or (vi) the failure of the Company to meet its financial projections. The Company has no Subsidiaries
except as set forth in Schedule 3(a). The outstanding shares of capital stock of each of the Subsidiaries have been duly
authorized and validly issued, are fully paid and non-assessable and are owned by the Company or another Subsidiary, if any, free
and clear of all liens, preemptive or similar rights, mortgages, defects, claims, pledges, charges, taxes, rights of first refusal,
encumbrances, security interests and other encumbrances (collectively, “Liens”) and equities and claims; and
no options, warrants or other rights to purchase, agreements or other obligations to issue or other rights to convert any obligations
into shares of capital stock or ownership interests in the Subsidiaries are outstanding.

 

(b)              
Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and
perform its obligations under this Agreement and each of the other agreements entered into by the parties hereto in connection
with the transactions contemplated by this Agreement (collectively, the “Transaction Documents”) and to issue
the Shares in accordance with the terms hereof and thereof. The execution and delivery of this Agreement and the other Transaction
Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby have been duly
authorized by the Company’s Board of Directors and other than (i) a Form D with the SEC and any other filings as may be required
by any state securities agencies and (ii) the 8-K Filing (collectively, the “Required Filings and Approvals”),
no further filing, consent or authorization is required by the Company, its Board of Directors or its stockholders. This Agreement
and the other Transaction Documents have been duly executed and delivered by the Company, and constitute the legal, valid and binding
obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability
may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or
similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies. Except as
set forth in Schedule 3(b) there are no stockholder agreements, voting agreements, or other similar arrangements with respect
to the Company’s capital stock to which the Company is a party or, to the actual knowledge after reasonable inquiry of the
Company’s chief executive officer, chief financial officer and general counsel, but without any obligation to conduct investigation
of anyone outside of the Company or its Subsidiaries (collectively, the “Company’s Knowledge”), between
or among any of the Company’s stockholders.

 

 

 

 

    	 	6	 

     

    

 

(c)              
Issuance of Shares. The issuance of the Shares is duly authorized and, upon issuance in accordance with the terms
of the Transaction Documents, the Shares shall be validly issued and free from all preemptive or similar rights (except for those
which have been validly waived prior to the date hereof), taxes, liens and charges and other encumbrances with respect to the issue
thereof and the Shares shall be fully paid and non-assessable with the holders being entitled to all rights accorded to a holder
of Preferred Stock. As of each Closing, a number of shares of Common Stock shall have been duly authorized and reserved for issuance
which equals at least the number of shares of Common Stock issuable upon conversion of the Shares purchased at such Closing. Upon
conversion of the Shares in accordance with the terms of the Certificate of Designation, the Underlying Shares when issued will
be validly issued, fully paid and non-assessable and free from all preemptive or similar rights, taxes, liens, charges and other
encumbrances with respect to the issue thereof, with the holders being entitled to the rights accorded to a holder of Common Stock.
Assuming the accuracy of each of the representations and warranties set forth in Section 2, the offer and issuance
by the Company of the Shares is exempt from registration under the 1933 Act.

 

(d)              
No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Shares and
the reservation for issuance and issuance of Underlying Shares) will not (i) result in a violation of the Articles of Incorporation
(as defined below) or Bylaws (as defined below) or other organizational documents of the Company or any of its Subsidiaries, any
capital stock of the Company or any of its Subsidiaries or bylaws of the Company or any of its Subsidiaries or (ii) except as set
forth in Schedule 3(d), conflict with, or constitute a default (or an event which with notice or lapse of time or both would
become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of,
any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, other than conflicts or defaults
that would not reasonably be expected to have a Material Adverse Effect, or (iii) result in a violation of any law, rule, regulation,
order, judgment or decree (including foreign, federal and state securities laws and regulations and the rules and regulations of
the OTCQX market (the “Principal Market”) and including all applicable foreign, federal, state laws, rules and
regulations) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its
Subsidiaries is bound or affected, assuming, with respect to subsections (ii) and (iii), the making and receipt of the Required
Filings and Approvals, other than violations that would not reasonably be expected to have a Material Adverse Effect.

 

(e)              
Consents. Other than the Required Filings and Approvals, the Company is not required to obtain any consent from,
authorization or order of, or make any filing or registration with, any court, governmental agency or any regulatory or self-regulatory
agency or any other Person in order for it to execute, deliver or perform any of its obligations under or contemplated by the Transaction
Documents, in each case, in accordance with the terms hereof or thereof. Other than the Required Filings and Approvals, all consents,
authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have
been obtained or effected on or prior to each Closing (or in the case of filings detailed above, will be made timely after each
Closing), and the Company is unaware of any facts or circumstances which might prevent the Company from obtaining or effecting
any of the registration, application or filings contemplated by the Transaction Documents. Except as set forth in Schedule 3(e),
the Company is not in violation of the listing requirements of the Principal Market and has no knowledge of any facts or circumstances
which would reasonably lead to the suspension of quotation of the Common Stock on the Principal Market in the foreseeable future.
The issuance by the Company of the Shares shall not have the effect of suspending of quotation of the Common Stock on the Principal
Market.

 

(f)               
Acknowledgment Regarding the Buyer’s Purchase of Shares. The Company acknowledges and agrees that the Buyer
is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions
contemplated hereby and thereby and that, except as set forth in Schedule 3(f), the Buyer is not (i) an officer or director
of the Company or any of its Subsidiaries, (ii) an “affiliate” of the Company or any of its Subsidiaries (as defined
in Rule 144), if any, or (iii) to the Company’s Knowledge, a “beneficial owner” of more than 10% of the Common
Stock (as defined for purposes of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “1934 Act”)).
The Company further acknowledges that the Buyer is not acting as a financial advisor or fiduciary of the Company or any of its
Subsidiaries (or in any similar capacity), if any, with respect to the Transaction Documents and the transactions contemplated
hereby and thereby, and any advice given by the Buyer or any of its representatives or agents in connection with the Transaction
Documents and the transactions contemplated hereby and thereby is merely incidental to the Buyer’s purchase of the Shares.
The Company further represents to the Buyer that the Company’s decision to enter into the Transaction Documents has been
based solely on the independent evaluation by the Company and its representatives.

 

 

 

    	 	7	 

     

    

 

(g)              
No General Solicitation; Placement Agent Fees. Neither the Company, nor any of its Subsidiaries or affiliates,
nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the
meaning of Regulation D) in connection with the offer or sale of the Shares. The Company shall be responsible for the payment of
any placement agent fees, financial advisory fees, or brokers’ commissions (other than for Persons engaged by the Buyer or
the Buyer’s investment advisor) relating to or arising out of the transactions contemplated hereby, in connection with the
sale of the Shares. The Company shall pay, and hold the Buyer harmless against, any liability, loss or expense (including, without
limitation, reasonable attorney’s fees and out-of-pocket expenses) arising in connection with any such claim.

 

(h)              
No Integrated Offering. None of the Company, its Subsidiaries or any of their affiliates, nor any Person acting
on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security,
under circumstances that would require registration of the issuance of any of the Shares under the 1933 Act, whether through integration
with prior offerings or otherwise. None of the Company, its Subsidiaries, any of their affiliates nor any Person acting on their
behalf will take any action or steps that would require registration of the issuance of any of the Securities under the 1933 Act.

 

(i)                
Application of Takeover Protections; Rights Agreement. The Company and its Board of Directors have taken all necessary
action, if any, in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison
pill (including, without limitation, any distribution under a rights agreement) or other similar anti-takeover provision under
the Articles of Incorporation, Bylaws or other organizational documents or the laws of the jurisdiction of its formation which
is or could become applicable to the Buyer as a result of the transactions contemplated by this Agreement, including, without limitation,
the Company’s issuance of the Securities and the Buyer’s ownership of the Securities. The Company and its Board of
Directors have taken all necessary action, if any, in order to render inapplicable any stockholder rights plan or similar arrangement
relating to accumulations of beneficial ownership of Preferred Stock or a change in control of the Company or any of its Subsidiaries.

 

(j)                
SEC Documents; Financial Statements. Except as disclosed in Schedule 3(j), during the two years prior
to the date hereof, the Company has timely filed all reports, schedules, forms, statements and other documents required to be filed
by it with the SEC pursuant to the reporting requirements of the 1934 Act (all of the foregoing filed prior to the date hereof
or prior to each Closing, and all exhibits included therein and financial statements, notes and schedules thereto and documents
incorporated by reference therein being hereinafter referred to as the “SEC Documents”). The Company has delivered
to the Buyer or its representatives, upon request, true, correct and complete copies of the SEC Documents not available on the
EDGAR system. As of their respective filing dates, the SEC Documents complied in all material respects with the requirements of
the 1934 Act applicable to the Company and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents,
and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. As of their respective filing dates, the financial statements of the
Company included in the SEC Documents (the “Financial Statements”) complied as to form in all material respects
with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial
statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), consistently
applied during the periods involved (except (i) as may be otherwise indicated in such Financial Statements or the notes thereto,
or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements)
and fairly present in all material respects the financial position of the Company and its Subsidiaries, as of the dates thereof
and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal
year-end audit adjustments which will not be material, either individually or in the aggregate). The Company is not currently contemplating
to amend or restate any of the Financial Statements, nor is the Company currently aware of facts or circumstances which would require
the Company to amend or restate any of the Financial Statements, in each case, in order for any of the Financial Statements to
be in material compliance with GAAP and the rules and regulations of the SEC. The Company has not been informed by its independent
accountants that they recommend that the Company amend or restate any of the Financial Statements or that there is any need for
the Company to amend or restate any of the Financial Statements.

 

 

 

    	 	8	 

     

    

 

(k)              
Absence of Certain Changes. Except as disclosed in Schedule 3(k)(i), since December 31, 2019, there has been
no  Material Adverse Effect. Except as disclosed in Schedule 3(k)(ii), since December 31, 2019, neither the Company nor any
of its Subsidiaries has (i) declared or paid any dividends, (ii) sold any assets, individually or in the aggregate, in excess of
$100,000 outside of the ordinary course of business or (iii) had capital expenditures, individually or in the aggregate, in excess
of $100,000. Neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to any law or statute
relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor to the Company’s Knowledge
does the Company or any Subsidiary believe that any of their respective creditors intend to initiate involuntary bankruptcy proceedings
or any actual knowledge of any fact which would reasonably lead a creditor to do so. The Company and its Subsidiaries as a whole
are not, as of the date hereof, and after giving effect to the transactions contemplated hereby to occur at each Closing, will
not be Insolvent (as defined below). For purposes of this Section 3(k), “Insolvent” means, with
respect to any Person, (w) the present fair saleable value of such Person’s assets is less than the amount required to pay
such Person’s total Indebtedness (as defined in Section 3(q)), (x) such Person is unable to pay its debts and
liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured, (y) such Person
intends to incur or believes that it will incur debts that would be beyond its ability to pay as such debts mature or (z) such
Person has unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted
and is proposed to be conducted.

 

(l)                
No Undisclosed Events, Liabilities, Developments or Circumstances. Since December 31, 2019, no event, liability,
development or circumstance has occurred or exists, or is contemplated to occur with respect to the Company, its Subsidiaries,
or their respective business, properties, prospects, operations or financial condition, that would constitute a Material Adverse
Effect.

 

(m)             
Conduct of Business; Regulatory Permits. Neither the Company nor any of its Subsidiaries is in violation of any term
of or in default under its Articles of Incorporation, any certificate of designation, preferences or rights of any other outstanding
series of preferred stock of the Company or any of its Subsidiaries or Bylaws or their organizational charter, certificate of formation
or certificate of incorporation or bylaws, respectively. The Company and each of its Subsidiaries have been in material compliance
with all Applicable Laws (as defined below) since the incorporation of the Company and will continue to operate in compliance with
all Applicable Laws. “Applicable Law” means applicable provisions of federal, state or local law (including
common law), statute, rule, regulation, order, permit, judgment, injunction, decree or other decision of any court or other tribunal
or governmental authority legally binding on the Company, its properties, its Subsidiaries, or their properties, including applicable
state or local laws with respect to cannabis, all as may be amended, but excluding the Controlled Substances Act (21 U.S.C. §801,
et. seq.) federal law that prohibits the cultivation, processing, transportation, sale or possession of Cannabis or parts
of Cannabis including particular cannabinoids, the sale or possession of cannabis paraphernalia, or advertising the sale of Cannabis,
products containing Cannabis, or Cannabis paraphernalia. “Cannabis” means a plant in the genus Cannabis
including Cannabis sativa, Cannabis indica, Cannabis ruderalis, and all subspecies, hybrids, or yet to be discovered subspecies
and hybrids, and including the federal law definitions of Marijuana. “Marijuana” means any material, compound,
derivative, mixture, product or preparation that contains any quantity of the substances listed on Schedule 1 of the Controlled
Substances Act or in its implementing regulations, including without limitation 21 C.F.R. § 1308.11, 21 U.S.C. § 802(6)
as “Marihuana” or “Tetrahydrocannabinols,” except Hemp, as defined in 7 U.S.C. § 1639o and except
Cannabis Plant Materials defined in 21 C.F.R. 1308.35 or which contains any of their salts, isomers and salts of isomers, or any
derivative or mixture thereof or any synthetic equivalent or which would be a “controlled substance analogue” manufactured,
formulated, sold, distributed, or marketed with the intent to avoid the provisions of existing drug laws as defined under 21 U.S.C.
§ 813. The Company and each of its Subsidiaries possess all material certificates, authorizations and permits issued by the
appropriate foreign, federal or state regulatory authorities necessary to conduct their respective businesses. All such certificates,
authorizations and permits are valid and in full force and effect. During the period since the Company’s Common Stock was
designated for quotation on the Principal Market, (i) the Common Stock has been designated for quotation on the Principal Market,
(ii) trading in the Common Stock has not been suspended by the SEC or the Principal Market and (iii) the Company has received
no communication, written or oral, from the SEC or the Principal Market regarding the suspension of quotation of the Common
Stock on the Principal Market.

 

(n)              
Sarbanes-Oxley Act. The Company is in compliance with any and all applicable requirements of the Sarbanes-Oxley Act
of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by
the SEC thereunder that are effective as of the date hereof.

 

 

 

 

    	 	9	 

     

    

 

(o)              
Transactions With Affiliates. Except as set forth in Schedule 3(o), none of the current officers, directors
or employees (including, without limitation, any family member or affiliate thereof) of the Company or any of its Subsidiaries
is presently a party to (or has previously been a party to) any transaction with the Company or any of its Subsidiaries (other
than for ordinary course services as employees, officers or directors), including any contract, agreement or other arrangement
providing for the furnishing of goods or services to or by, providing for rental of real or personal property to or from, or otherwise
requiring payments to or from any such officer, director or employee or, to the Company’s Knowledge, any corporation, partnership,
trust or other Person in which any such officer, director, or employee (or family member or affiliate thereof) has a substantial
interest or is an employee, officer, director, trustee or partner.

 

(p)              
Equity Capitalization.  As of February 17, 2021, the authorized capital stock of the Company consists of (i)
250,000,000 shares of Common Stock, of which 42,601,768 are issued and outstanding, 18,500,00 shares are reserved for issuance
pursuant to the Company’s stock option and purchase plans and 45,563,701 shares are reserved for issuance pursuant to securities
(other than the aforementioned options) exercisable or exchangeable for, or convertible into, Common Stock and (ii) 10,000,000
shares of preferred stock, par value $0.001 per share, 28,485 of which are designated and issued and outstanding. 432,732 shares
of Common Stock are held in treasury. All of such outstanding shares are duly authorized, validly issued and are fully paid and
non-assessable. 9,570,548 shares of the Company’s issued and outstanding Common Stock on the date hereof are as of the date
hereof owned by Persons who are “affiliates” (as defined in Rule 405 of the 1933 Act) of the Company or any of its
Subsidiaries. (i) Except as disclosed in Schedule 3(p), none of the Company’s or any Subsidiary’s
capital stock is subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by
the Company or any Subsidiary; (ii) except as disclosed in Schedule 3(p), there are no outstanding options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into, or exercisable or exchangeable for, any capital stock of the Company or any of its Subsidiaries, or contracts, commitments,
understandings or arrangements by which the Company or any of its Subsidiaries, is or may become bound to issue additional capital
stock of the Company or any of its Subsidiaries, or options, warrants, scrip, rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any capital stock
of the Company or any of its Subsidiaries; (iii) except as disclosed in Schedule 3(p), there are no outstanding
debt securities, notes, credit agreements, credit facilities or other agreements, documents or instruments evidencing Indebtedness
of the Company or any of its Subsidiaries, or by which the Company or any of its Subsidiaries, is or may become bound; (iv) except
as disclosed in Schedule 3(p), there are no financing statements securing obligations in any amounts filed in
connection with the Company or any of its Subsidiaries; (v) except as disclosed in Schedule 3(p), there are no agreements
or arrangements (other than as set forth herein) under which the Company or any of its Subsidiaries, is obligated to register the
sale of any of their securities under the 1933 Act; (vi) except as disclosed in Schedule 3(p), there are no outstanding
securities or instruments of the Company or any of its Subsidiaries, which contain any redemption or similar provisions, and there
are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become
bound to redeem a security of the Company or any of its Subsidiaries; (vii) except as disclosed in Schedule 3(p), there
are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of
the Shares; (viii) except as disclosed in Schedule 3(p), neither the Company nor any Subsidiary, if any, has any stock
appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement; and (ix) neither the Company
nor any of its Subsidiaries have any material non-public information, including any material liabilities or obligations, that are
required to be disclosed in the SEC Documents which are not so disclosed in the SEC Documents. True, correct and complete copies
of the Company’s articles of incorporation, as amended and as in effect on the date hereof (the “Articles of Incorporation”),
and the Company’s bylaws, as amended and as in effect on the date hereof (the “Bylaws”), and the terms
of all securities convertible into, or exercisable or exchangeable for, Common Stock and the material rights of the holders thereof
in respect thereto have heretofore been filed as part of the SEC Documents. Except as set forth in Schedule 3(p), each
stock option granted by the Company was granted (x) in accordance with the terms of the applicable stock option plan of the Company
and (y) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would
be considered granted under GAAP and applicable law. To the Company’s Knowledge, no stock option granted under the Company’s
stock option plan has been backdated. To the Company’s Knowledge, the Company has not granted, and there is no and has been
no policy or practice of the Company to grant, stock options prior to, or otherwise coordinate the grant of stock options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.

 

 

 

    	 	10	 

     

    

 

(q)              
Indebtedness and Other Contracts. Neither the Company nor any of its Subsidiaries, (i) except as disclosed in Schedule
3(q), has any outstanding Indebtedness (as defined below), (ii) except as disclosed in the SEC Documents, is a party to any
material definitive agreement (as defined in Item 1.01(b) of the Current Report on Form 8-K), or (iii) except as disclosed in Schedule
3(q), neither the Company nor such Subsidiary, nor any other party to a material definitive agreement (as defined in Item 1.01(b)
of the Current Report on Form 8-K) is in material violation of any term of, or in default under, such material definitive agreement,
including any material definitive agreement relating to any Indebtedness. For purposes of this Agreement: (x) “Indebtedness”
of any Person means, without duplication (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed
as the deferred purchase price of property or services (including, without limitation, “capital leases” in accordance
with GAAP, consistently applied during the periods involved) (other than trade payables entered into in the ordinary course of
business consistent with past practice), (C) all reimbursement or payment obligations with respect to letters of credit, surety
bonds and other similar instruments, (D) all obligations evidenced by notes, bonds, debentures or similar instruments, including
obligations so evidenced incurred in connection with the acquisition of property, assets or businesses, (E) all indebtedness created
or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect
to any property or assets acquired with the proceeds of such indebtedness (even though the rights and remedies of the seller or
bank under such agreement in the event of default are limited to repossession or sale of such property), (F) all monetary
obligations under any leasing or similar arrangement which, in connection with GAAP, consistently applied for the periods covered
thereby, is classified as a capital lease, (G) all indebtedness referred to in clauses (A) through (F) above secured by (or
for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any mortgage, claim,
lien, tax, right of first refusal, pledge, charge, security interest or other encumbrance upon or in any property or assets (including
accounts and contract rights) owned by any Person, even though the Person which owns such assets or property has not assumed or
become liable for the payment of such indebtedness, and (H) all Contingent Obligations in respect of indebtedness or obligations
of others of the kinds referred to in clauses (A) through (G) above; and (y) “Contingent Obligation” means,
as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any indebtedness, capital
lease, dividend or other obligation of another Person if the primary purpose or intent of the Person incurring such liability,
or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged,
or that any agreements relating thereto will be complied with, or that the holders of such liability will be protected (in whole
or in part) against loss with respect thereto.

 

(r)               
Absence of Litigation. Except as set forth in the SEC Documents, there is no material action, suit, proceeding,
inquiry or investigation before or by the Principal Market, any court, public board, arbitrator, panel, government agency, self-regulatory
organization or body pending or, to the Company’s Knowledge, threatened against or affecting the Company or any of its Subsidiaries,
the Preferred Stock, the consummation of the Proposed Transaction or any of the Company’s or its Subsidiaries’ officers
or directors, whether of a civil or criminal nature or otherwise, in their capacities as such. “Proposed Transaction”
means the acquisition by the Company or one or more direct or indirect wholly-owned Subsidiaries of the Company of substantially
all of the assets of Starbuds Aurora LLC, SB Arapahoe LLC, Citi-Med LLC, Starbuds Louisville LLC and KEW LLC. To the Company’s
Knowledge, no director, officer or employee of the Company or any of its Subsidiaries has willfully violated 18 U.S.C. §1519
or engaged in spoliation in reasonable anticipation of litigation. Without limitation of the foregoing, there has not been, and
to the Company’s Knowledge, there is not pending, contemplated or anticipated, any inquiry or investigation by the SEC involving
the Company, any of its Subsidiaries or any current or former director or officer of the Company or any of its Subsidiaries. The
SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company
under the 1933 Act or the 1934 Act. Neither the Company nor any of its Subsidiaries is subject to any order, writ, judgment, injunction,
decree, determination or award of any governmental entity.

 

(s)               
Tax Status. The Company and each of its Subsidiaries (i) has timely made or filed all material foreign, federal and
state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has
timely paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
on such returns, reports and declarations, except those being contested in good faith and (iii) has set aside on its books adequate
reserves for the payment of all unpaid taxes. There are no unpaid taxes in any material amount claimed to be due by the taxing
authority of any jurisdiction, except for those being contested in good faith, and the officers of the Company and its Subsidiaries
know of no basis for any such claim.

 

 

 

 

    	 	11	 

     

    

 

(t)               
Internal Accounting and Disclosure Controls. The Company and each of its Subsidiaries, maintain a system of internal
accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s
general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in
conformity with GAAP, consistently applied during the periods involved, and Applicable Law, and to maintain asset and liability
accountability, (iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general
or specific authorization and (iv) the recorded accountability for assets and liabilities is compared with the existing assets
and liabilities at reasonable intervals and appropriate action is taken with respect to any difference. The Company maintains disclosure
controls and procedures (as such term is defined in Rule 13a-15 under the 1934 Act) that are effective in ensuring that information
required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is recorded, processed, summarized
and reported, within the time periods specified in the rules and forms of the SEC, including, without limitation, controls and
procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits
under the 1934 Act is accumulated and communicated to the Company’s management, including its principal executive officer
or officers and its principal financial officer or officers, as appropriate, to allow timely decisions regarding required disclosure.
Except as set forth in Schedule 3(s), during the twelve months prior to the date hereof neither the Company nor any of its
Subsidiaries, has received any written notice or correspondence from any accountant relating to any material weakness in any part
of the system of internal accounting controls of the Company or any of its Subsidiaries.

 

(u)              
Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company
or any of its Subsidiaries and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company
in its 1934 Act filings and is not so disclosed or that otherwise has had or would be reasonably likely to have a Material Adverse
Effect.

 

(v)              
Investment Company Status. Neither the Company nor any of its Subsidiaries, is, and upon consummation of the sale
of the Shares, and for so long as the Buyer holds any Shares, will not be, an “investment company,” an affiliate of
an “investment company,” a company controlled by an “investment company” or an “affiliated person”
of, or “promoter” or “principal underwriter” for, an “investment company” as such terms are
defined in the Investment Company Act of 1940, as amended.

 

(w)             
Acknowledgement Regarding the Buyer’s Trading Activity. The Company acknowledges and agrees that, except as
otherwise set forth herein or in any other Transaction Document, (i) the Buyer has not been asked to agree, nor has the Buyer agreed,
to desist from purchasing or selling, long and/or short, securities of the Company, or “derivative” securities based
on securities issued by the Company or to hold the Securities for any specified term; (ii) the Buyer, and counter-parties
in “derivative” transactions to which the Buyer is a party, directly or indirectly, presently may have a “short”
position in the Common Stock; (iii) the Buyer shall not be deemed to have any affiliation with or control over any arm’s
length counter-party in any “derivative” transaction; and (iv) the Buyer may rely on the Company’s obligation
to timely deliver shares of Common Stock as and when required pursuant to the Transaction Documents for purposes of effecting trading
in the Common Stock of the Company. The Company further understands and acknowledges that (a) the Buyer may engage in hedging and/or
trading activities at various times during the period that the Securities are outstanding, and (b) such hedging and/or trading
activities, if any, can reduce the value of the existing stockholders’ equity interest in the Company both at and after the
time the hedging and/or trading activities are being conducted. The Company acknowledges that such aforementioned hedging and/or
trading activities do not constitute a breach of this Agreement or any of the documents executed in connection herewith.

 

(x)              
Manipulation of Price. The Company has not, and, to the Company’s Knowledge, no one acting on its behalf
has, (i) taken, directly or indirectly, any action designed to cause or to result, or that could reasonably be expected to cause
or result, in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of
any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities
(other than to placement agents), (iii) paid or agreed to pay to any person any compensation for soliciting another to purchase
any other securities of the Company, or (iv) paid or agreed to pay any Person for research services with respect to any securities
of the Company or any of its Subsidiaries.

 

 

 

 

    	 	12	 

     

    

 

(y)              
Shell Company Status. The Company is not, and has never been, an issuer identified in, or subject to, Rule 144(i)(1)
of the 1933 Act.

 

(z)              
Compliance with Anti-Money Laundering Laws. Other than as a result of non-compliance with the Controlled Substances
Act (21 U.S.C. §801, et. seq.)that prohibits the cultivation, processing, transportation, sale or possession of Cannabis
or parts of Cannabis including particular cannabinoids, the sale or possession of Cannabis paraphernalia, or advertising the sale
of Cannabis, products containing Cannabis, or Cannabis paraphernalia, the operations of the Company and its Subsidiaries are and
have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements and all other
applicable U.S. and non-U.S. anti-money laundering laws, rules and regulations, including, but not limited to, those of the Currency
and Foreign Transactions Reporting Act of 1970, as amended, the United States Bank Secrecy Act, as amended by the USA PATRIOT Act
of 2001, and the United States Money Laundering Control Act of 1986 (18 U.S.C. §§1956 and 1957), as amended, as well
as the implementing rules and regulations promulgated thereunder, and the applicable money laundering statutes of all applicable
jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered
or enforced by any governmental agency or self-regulatory body (collectively, the “Anti-Money Laundering Laws”),
and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any of its Subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the Company’s Knowledge,
threatened.

 

(aa)           
Sanctions. Neither the Company nor any of its Subsidiaries, nor any director, officer, employee, agent, affiliate
or other person associated with or acting on behalf of the Company or any of its Subsidiaries or affiliates is, or is directly
or indirectly owned or controlled by, a Person that is currently the subject or the target of any sanctions administered or enforced
by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury
or the U.S. Departments of State or Commerce and including, without limitation, the designation as a “Specially Designated
National” or on the “Sectoral Sanctions Identifications List”, collectively “Blocked Persons”),
the United Nations Security Council, the European Union, Her Majesty’s Treasury or any other relevant sanctions authority
(collectively, “Sanctions Laws”); neither the Company, any of its Subsidiaries, nor any director, officer, employee,
agent, affiliate or other person associated with or acting on behalf of the Company or any of its Subsidiaries or affiliates, is
located, organized or resident in a country or territory that is the subject or target of a comprehensive embargo or Sanctions
Laws prohibiting trade with the country or territory, including, without limitation, Crimea, Cuba, Iran, North Korea, Sudan and
Syria (each, a “Sanctioned Country”); the Company maintains in effect and enforces policies and procedures designed
to ensure compliance by the Company and its Subsidiaries with applicable Sanctions Laws; neither the Company, any of its Subsidiaries,
nor any director, officer, employee, agent, affiliate or other person associated with or acting on behalf of the Company or any
of its Subsidiaries or affiliates, acting in any capacity in connection with the operations of the Company, conducts any business
with or for the benefit of any Blocked Person or engages in making or receiving any contribution of funds, goods or services to,
from or for the benefit of any Blocked Person, or deals in, or otherwise engages in any transaction relating to, any property or
interests in property blocked or subject to blocking pursuant to any applicable Sanctions Laws; no action of the Company or any
of its Subsidiaries in connection with (i) the execution, delivery and performance of this Agreement and the other Transaction
Documents, (ii) the issuance and sale of the Securities, or (iii) the direct or indirect use of proceeds from the Securities or
the consummation of any other transaction contemplated hereby or by the other Transaction Documents or the fulfillment of the terms
hereof or thereof, will result in the proceeds of the transactions contemplated hereby and by the other Transaction Documents being
used, or loaned, contributed or otherwise made available, directly or indirectly, to any Subsidiary, joint venture partner or other
person or entity, for the purpose of (i) unlawfully funding or facilitating any activities of or business with any person that,
at the time of such funding or facilitation, is the subject or target of Sanctions Laws, (ii) unlawfully funding or facilitating
any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any Person
(including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions Laws.
For the past five years, the Company and its Subsidiaries have not knowingly engaged in and are not now knowingly engaged in any
dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of
Sanctions Laws or with any Sanctioned Country.

 

 

 

 

    	 	13	 

     

    

 

(bb)          
Anti-Bribery. Neither the Company nor any of the Subsidiaries has made any contribution or other payment to any official
of, or candidate for, any federal, state or foreign office in violation of any law. Neither the Company, nor any of its Subsidiaries
or affiliates, nor any director, officer, agent, employee or other person associated with or acting on behalf of the Company, or
any of its Subsidiaries or affiliates, has (i) used any funds for any unlawful contribution, gift, entertainment or other unlawful
expense relating to political activity, (ii) made any direct or indirect unlawful payment to any foreign or domestic government
official or employee, to any employee or agent of a private entity with which the Company does or seeks to do business or to foreign
or domestic political parties or campaigns, (iii) violated or is in violation of any provision of any Applicable Law implementing
the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions or any applicable provision
of the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other similar law of any other
jurisdiction in which the Company operates its business, including, in each case, the rules and regulations thereunder (the “Anti-Bribery
Laws”), (iv) taken, is currently taking or will take any action in furtherance of an offer, payment, gift or anything
else of value, directly or indirectly, to any person while knowing that all or some portion of the money or value will be offered,
given or promised to anyone to improperly influence official action, to obtain or retain business or otherwise to secure any improper
advantage or (v) otherwise made any offer, bribe, rebate, payoff, influence payment, unlawful kickback or other unlawful payment;
the Company and each of its respective Subsidiaries has instituted and has maintained, and will continue to maintain, policies
and procedures reasonably designed to promote and achieve compliance with the laws referred to in (iii) above and with this representation
and warranty; none of the Company, nor any of its Subsidiaries or affiliates will directly or indirectly use the proceeds of the
Shares or lend, contribute or otherwise make available such proceeds to any subsidiary, affiliate, joint venture partner or other
person or entity for the purpose of financing or facilitating any activity that would violate the laws and regulations referred
to in (iii) above; there are, and have been, no allegations, investigations or inquiries with regard to a potential violation of
any Anti-Bribery Laws by the Company, its Subsidiaries or affiliates, or any of their respective current or former directors, officers,
employees, stockholders, representatives or agents, or other persons acting or purporting to act on their behalf.

 

(cc)          
No Additional Agreements. Except as set forth in Schedule 3(cc), the Company does not have any agreement or
understanding with the Buyer with respect to the transactions contemplated by the Transaction Documents.

 

(dd)          
Disclosure. All disclosure provided to the Buyer regarding the Company and its Subsidiaries, their businesses and
the transactions contemplated hereby, including the schedules to this Agreement and the Confidential PPM, furnished by or on behalf
of the Company or any of its Subsidiaries, is true and correct and does not contain any untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under
which they were made, not misleading. All of the written information furnished after the date hereof by or on behalf of the Company
or any of its Subsidiaries, to the Buyer pursuant to or in connection with this Agreement and the other Transaction Documents,
taken as a whole, will be true and correct in all material respects as of the date on which such information is so provided and
will not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
made therein, in the light of the circumstances under which they are made, not misleading. Each press release issued by the Company
or any of its Subsidiaries, during the twelve months preceding the date of this Agreement did not at the time of release contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading. No event or circumstance
has occurred or information exists with respect to the Company or any of its Subsidiaries, or its or their business, properties,
liabilities, prospects, operations (including results thereof) or conditions (financial or otherwise), which, under Applicable
Law, requires public disclosure at or before the date hereof or announcement by the Company but which has not been so publicly
disclosed. The Company understands and confirms that the Buyer will rely on the foregoing representations in effecting the transactions
of securities of the Company. The Company acknowledges and agrees that the Buyer does not make and have not made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 2.

 

 

 

 

    	 	14	 

     

    

 

(ee)           
No Disqualification Events. With respect to Securities to be offered and sold hereunder in reliance on Rule
506(b) under the 1933 Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer,
other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company’s
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule
405 under the 1933 Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person”
and, together, “Issuer Covered Persons”) is subject to any of the “Bad Actor” disqualifications
described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a “Disqualification Event”), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person
is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under
Rule 506(e), and has furnished to the Buyer a copy of any disclosures provided thereunder.

 

(ff)            
Other Covered Persons. Except as set forth on Schedule 3(ff), the Company is not aware of any Person that
has been or will be paid (directly or indirectly) remuneration for solicitation of the Buyer or potential purchasers in connection
with the sale of the Securities.

 

(gg)          
Intellectual Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use
all trademarks, trade names, service marks, service mark registrations, service names, original works of authorship, patents, patent
rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and other intellectual property
rights and all applications and registrations therefor (“Intellectual Property Rights”) necessary to conduct
their respective businesses as now conducted. To the Company’s Knowledge, there is not any infringement by the Company or
its Subsidiaries of Intellectual Property Rights of others. There is no claim, action or proceeding being made or brought, or to
the Company’s Knowledge, being threatened, against the Company or any of its Subsidiaries regarding its Intellectual Property
Rights, except where such claim, action or proceeding is not reasonably likely to result in a Material Adverse Effect. Neither
the Company nor any of its Subsidiaries has received any written notice alleging any such infringement or claim, action or proceeding.

 

(hh)          
Title. Each of the Company and its Subsidiaries holds good title, or a valid leasehold interests in, to all real
property, leases in real property, facilities or other interests in real property owned or held by the Company or any of its Subsidiaries
that is material to the business of the Company (the “Real Property”). The Real Property is free and clear of
all Liens and is not subject to any rights of way, building use restrictions, exceptions, variances, reservations, or limitations
of any nature except for (a) Liens for current taxes not yet due and payable, (b) zoning laws and other land use restrictions that
do not impair the present or anticipated use of the property subject thereto and (c) those that are not likely to result in a Material
Adverse Effect. Any Real Property held under lease by the Company or any of its Subsidiaries are held by them under valid, subsisting
and enforceable leases with such exceptions as are not material and do not interfere in any material respect with the use made
and proposed to be made of such property and buildings by the Company or any of its Subsidiaries.

 

(ii)            
Fixtures and Equipment. Each of the Company and its Subsidiaries (as applicable) has good title to, or a valid leasehold
interest in, all material tangible personal property, equipment, improvements, fixtures, and other personal property and appurtenances
that are used by the Company or its Subsidiary in connection with the conduct of its business (the “Fixtures and Equipment”).
Each of the Company’s and its Subsidiary’s Fixtures and Equipment are structurally sound, are in good operating condition
and repair, are adequate for the uses to which they are being put, are not in need of maintenance or repairs except for ordinary,
routine maintenance and repairs and are sufficient for the conduct of the Company’s and/or its Subsidiaries’ businesses
(as applicable) in the manner as conducted prior to each Closing. Each of the Company and its Subsidiaries owns all of its Fixtures
and Equipment free and clear of all Liens except for (i) Liens for current taxes not yet due and payable, and (ii) zoning laws
and other land use restrictions that do not impair the present or anticipated use of the property subject thereto.

 

 

 

 

    	 	15	 

     

    

 

(jj)             
Environmental Laws.

 

(i)              
The Company and its Subsidiaries (A) are in compliance with any and all Environmental Laws (as defined below), other than
those that are not likely to result in a Material Adverse Effect, (B) have received all permits, licenses or other approvals required
of them under applicable Environmental Laws to conduct their respective businesses and (C) are in compliance with all terms and
conditions of any such permit, license or approval where, except in each of the foregoing clauses (A), (B) and (C), where the failure
to so comply or having such permits, licenses or other approval would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect. The term “Environmental Laws” means all federal, state, local or foreign
laws relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface
water, groundwater, land surface or subsurface strata), including, without limitation, laws relating to emissions, discharges,
releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively,
“Hazardous Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution,
use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees,
demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations issued,
entered, promulgated or approved thereunder.

 

(ii)             
No Hazardous Materials:

 

(1)              
to the Company’s Knowledge, have been disposed of or otherwise released by the Company or any of its Subsidiaries
from any Real Property of the Company or any of its Subsidiaries in violation of any Environmental Laws; or

 

(2)              
to the Company’s Knowledge, are present on, over, beneath, in or upon any Real Property or any portion thereof in
quantities that would constitute a violation of any Environmental Laws. To the Company’s Knowledge, no prior use by the Company
or any of its Subsidiaries of any Real Property has occurred that violates any Environmental Laws, which violation would have a
Material Adverse Effect.

 

(iii)           
To the Company’s Knowledge, neither the Company nor any of its Subsidiaries knows of any other person who or entity
which has stored, treated, recycled, disposed of or otherwise located on any Real Property any Hazardous Materials, including,
without limitation, such substances as asbestos and polychlorinated biphenyls.

 

(iv)           
To the Company’s Knowledge, none of the Real Property is on any federal or state “Superfund” list or Liability
Information System (“CERCLIS”) list or any state environmental agency list of sites under consideration for
CERCLIS, nor subject to any environmental related Liens.

 

(kk)          
Management. During the past five year period, to the Company’s Knowledge, no current named executive officer
(as defined in Item 402 of Regulation S-K) or director has been the subject of:

 

(i)               
a petition under bankruptcy laws or any other insolvency or moratorium law or the appointment by a court of a receiver,
fiscal agent or similar officer for such Person, or any partnership in which such person was a general partner, or any corporation
or business association of which such person was an executive officer;

 

(ii)             
a conviction in a criminal proceeding or a named subject of a pending criminal proceeding (excluding traffic violations
that do not relate to driving while intoxicated or driving under the influence);

 

 

 

 

    	 	16	 

     

    

 

(iii)           
any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
permanently or temporarily enjoining any such person from, or otherwise limiting, the following activities:

 

(1)              
Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker,
leverage transaction merchant, any other person regulated by the United States Commodity Futures Trading Commission or an associated
person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person,
director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing
any conduct or practice in connection with such activity;

 

(2)              
Engaging in any particular type of business practice; or

 

(3)              
Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any
violation of securities laws or commodities laws;

 

(iv)            
any order, judgment or decree, not subsequently reversed, suspended or vacated, of any authority barring, suspending or
otherwise limiting for more than 60 days the right of any such person to engage in any activity described in the preceding sub
paragraph, or to be associated with persons engaged in any such activity;

 

(v)              
a finding by a court of competent jurisdiction in a civil action or by the SEC or other authority to have violated any securities
law, regulation or decree and the judgment in such civil action or finding by the SEC or any other authority has not been subsequently
reversed, suspended or vacated; or

 

(vi)            
a finding by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have
violated any federal commodities law, and the judgment in such civil action or finding has not been subsequently reversed, suspended
or vacated.

 

(ll)             
Cybersecurity. The Company and its Subsidiaries’ information technology assets and equipment, computers, systems,
networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate
for, and operate and perform in all material respects as required in connection with the operation of the business of the Company
and its Subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware
and other corruptants. The Company and its Subsidiaries have implemented and maintained commercially reasonable physical, technical
and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information
and the integrity, continuous operation, redundancy and security of all IT Systems and data, including “Personal Data,”
used in connection with their businesses. “Personal Data” means (i) a natural person’s name, street address,
telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number,
passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify
as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) “personal data”
as defined by the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679); and (iv) any other
piece of information that allows the identification of such natural person, or his or her family, or permits the collection or
analysis of any data related to an identified person’s health or sexual orientation. To the Company’s Knowledge, there
have been no material breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been
remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or
investigations relating to the same. The Company and its Subsidiaries are presently in material compliance with all applicable
laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority,
internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection
of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.

 

 

 

 

    	 	17	 

     

    

 

(mm)     
Compliance with Data Privacy Laws. The Company and its Subsidiaries are, and at all prior times were, in material
compliance with all applicable state and federal data privacy and security laws and regulations, and the Company and its Subsidiaries
have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently are in compliance
with, the GDPR (EU 2016/679) (collectively, the “Privacy Laws”). To ensure compliance with the Privacy Laws,
the Company and its Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance
in all material respects with their policies and procedures relating to data privacy and security and the collection, storage,
use, disclosure, handling, and analysis of Personal Data (the “Policies”). The Company and its Subsidiaries
have at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements,
and none of such disclosures made or contained in any Policy have, to the Company’s Knowledge, been inaccurate or in violation
of any applicable laws and regulatory rules or requirements in any material respect. To the Company’s Knowledge, neither
the Company nor any Subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or
potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected
to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation,
or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any
obligation or liability under any Privacy Law.

 

(nn)          
Transfer Taxes. All transfer, stamp, registration, court or documentary, recording, filing or other similar taxes
(other than taxes imposed on or measured by net income (however denominated)) which are required to be paid by the Company in connection
with the issuance, registration, sale or transfer of the Securities to be sold to the Buyer hereunder will be, or will have been,
fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with in all material
respects.

 

(oo)          
Insurance. The Company and each of its Subsidiaries, if any, are insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses
in which the Company and its Subsidiaries, if any, are engaged. Neither the Company nor any such Subsidiary, if any, has been refused
any insurance coverage sought or applied for and, to the Company’s Knowledge, neither the Company nor any such Subsidiary,
if any, has any reason to believe that it will be unable to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have
a Material Adverse Effect.

 

(pp)           
U.S. Real Property Holding Corporation. Neither the Company nor any of its Subsidiaries, if any, is, or has ever
been, a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended,
and the Company and each Subsidiary shall so certify upon the Buyer’s request.

 

(qq)           
No Disagreements with Accountants and Lawyers. There are no material disagreements of any kind presently existing,
or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed
by the Company and the Company is current with respect to any fees owed to its accountants and lawyers which could affect the Company’s
ability to perform any of its obligations under any of the Transaction Documents.

 

4.                 
COVENANTS.

 

(a)              
Best Efforts. Each party hereto shall use its best efforts to timely satisfy each of the conditions to be satisfied
by it as provided in Sections 5 and 6.

 

 

 

 

    	 	18	 

     

    

 

(b)              
Form D and Blue Sky. The Company agrees to file a Form D with respect to the Securities as required under Regulation
D and to provide a copy thereof to the Buyer promptly after such filing. The Company shall, on or before each Closing, take such
action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Securities
for sale to the Buyer at such Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws of
the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action
so taken to the Buyer on or prior to each Closing. The Company shall make all filings and reports relating to the offer and sale
of the Securities required under applicable securities or “Blue Sky” laws of the states of the United States following
each Closing.

 

(c)              
Reporting Status. Until the date on which the Buyer does not hold any Shares (the “Reporting Period”),
the Company shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act (reports filed in compliance
with the time period specified in Rule 12b-25 promulgated under the 1934 Act or SEC or SEC staff issued relief shall be considered
timely for this purpose), and the Company shall not terminate its status as an issuer required to file reports under the 1934 Act
even if the 1934 Act or the rules and regulations thereunder would no longer require or otherwise permit such termination,
and the Company shall take all actions necessary to maintain its eligibility to register the Underlying Shares for resale by the
Buyer on Form S-1.

 

(d)              
Use of Proceeds. The Company will use the proceeds from each Closing to consummate the Proposed Transaction and pay
costs and expenses incurred in connection therewith. In furtherance thereof, the Company agrees to retain the net proceeds from
each Closing in its bank account(s) and use such proceeds solely for the purposes of consummating the Proposed Transaction and
paying costs and expenses incurred in connection therewith. In the event the Proposed Transaction does not close on or before March
3, 2021, the Purchase Price paid to the Company shall be refunded to the Buyer in full.

 

(e)              
Financial Information. The Company agrees to send the following to the Buyer so long as it holds Shares during the
Reporting Period (i) unless the following are filed with the SEC through EDGAR and are available to the public through the EDGAR
system, within one Business Day after the filing thereof with the SEC, a copy of its Annual Reports on Form 10-K, any Quarterly
Reports on Form 10-Q, any Current Reports on Form 8-K (or any analogous reports under the 1934 Act) and any registration statements
(other than on Form S-8) or amendments filed pursuant to the 1933 Act, and (ii) copies of any notices and other information made
available or given to the stockholders of the Company generally, contemporaneously with the making available or giving thereof
to the stockholders. As used herein, “Business Day” means any day other than Saturday, Sunday or other day on
which commercial banks in The City of New York are authorized or required by law to remain closed.

 

(f)               
Listing. The Company shall promptly secure the listing of all of the Underlying Shares upon each national securities
exchange and automated quotation system, if any, upon which the Common Stock is then listed (subject to official notice of issuance)
and shall maintain such listing of all Underlying Shares from time to time issuable under the terms of the Preferred Stock. For
so long as the Buyer owns any Shares, (i) the Company shall maintain the authorization for quotation of the Common Stock on the
Principal Market or The New York Stock Exchange, the NYSE American, the Nasdaq Global Market, the Nasdaq Global Select Market,
the OTC Bulletin Board, the OTCQB or the OTCQX (or any successors to any of the foregoing) (“Trading Market”),
and (ii) neither the Company nor any of its Subsidiaries shall take any action which would be reasonably expected to result in
the suspension of quotation of the Common Stock on the Principal Market other than in connection with, as a result of or after
listing of the Common Stock on The New York Stock Exchange, the NYSE American, the Nasdaq Global Market, the Nasdaq Global Select
Market, or any other recognized stock exchange in North America, including, without limitation, the Toronto Stock Exchange, the
TSX Venture Exchange, the NEO Exchange Inc. or the Canadian Securities Exchange (or any successors to any of the foregoing). The
Company shall pay all fees and expenses in connection with satisfying its obligations under this Section 4(f).

 

(g)              
Fees. The Company shall be responsible for the payment of any placement agent fees, financial advisory fees, or broker’s
commissions (other than those for Persons engaged by the Buyer) relating to or arising out of the transactions contemplated hereby,
including, without limitation, any fees or commissions payable to placement agents, including any reasonable legal fees and expenses
of such placement agents. The Company shall pay, and hold the Buyer harmless against, any liability, loss or expense (including,
without limitation, reasonable attorney’s fees and out-of-pocket expenses) arising in connection with any claim relating
to any such payment. Except as otherwise set forth in the Transaction Documents, each party to this Agreement shall bear its own
expenses in connection with the sale of the Shares to the Buyer.

 

 

 

 

    	 	19	 

     

    

 

(h)              
Disclosure of Transactions and Other Material Information. On or before 9:00 AM New York City time four Business
Days after the date hereof, the Company (A) may issue a press release disclosing all material terms of the transactions contemplated
hereby and (B) shall file a Current Report on Form 8-K describing the terms of the transactions contemplated by the Transaction
Documents in the form required by the 1934 Act and attaching the material Transaction Documents to the extent required by law (the
“8-K Filing”). Subject to the foregoing, neither the Company or its Subsidiaries nor the Buyer shall issue any
press releases or any other public statements with respect to the transactions contemplated hereby; provided, however, that the
Company shall be entitled, without the prior approval of the Buyer, to make any press release or other public disclosure with respect
to such transactions (i) in substantial conformity with the 8-K Filing and contemporaneously therewith and (ii) as is required
by Applicable Law. Except for any registration statement filed in accordance with this Agreement, the 8-K Filing and as required
by Applicable Law and Trading Market regulations, without the prior written consent of the Buyer, neither the Company nor any of
its Subsidiaries or affiliates shall disclose the name of the Buyer in any filing, announcement, release or otherwise.

 

(i)                
Reservation of Shares of Common Stock. So long as the Buyer owns any Shares, the Company shall take all action necessary
to at all times after the date hereof have authorized, and reserved for the purpose of issuance, no less than the number of
shares of Common Stock issuable upon conversion of the Shares then outstanding based on the then current conversion price. If at
any time the number of shares of Common Stock so authorized and reserved for issuance is not sufficient to meet the foregoing obligation,
the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares of Common
Stock, including, without limitation, calling a special meeting of stockholders to authorize additional shares of Common Stock
to meet such obligation.

 

(j)                
Buyer’s Lock-Up. Notwithstanding anything to the contrary contained herein, the Buyer agrees that the Buyer
will not (and any transferee of Shares held or formerly held by the Buyer may not), without the prior written consent of the Company,
directly or indirectly, assign, sell, pledge, contract to sell (including any short sale), grant any option to purchase, enter
into any contract to sell or otherwise dispose of or transfer (collectively, “Transfer”) any Underlying Shares
(as defined below) before and including the first anniversary of the date of the Buyer’s acquisition of the Shares to which
such Underlying Shares relate (the “Issue Date”). Thereafter, the Buyer will only (and any transferee of Shares
held or formerly held by the Buyer may only) Transfer (i) up to an aggregate of 25% of such Underlying Shares at any time following
the first anniversary of the Issue Date until the eighteen month anniversary of the Issue Date, (ii) together with any Underlying
Shares Transferred under clause (i), up to an aggregate of 50% of such Underlying Shares at any time following the eighteen month
anniversary of the Issue Date until the second anniversary of the Issue Date, and (iii) all of such Underlying Shares any time
following the second anniversary of the Issue Date; provided, however, that the Buyer may Transfer all of such Underlying Shares
at any time following the first Listing Event that occurs after the Issue Date; provided further, that this Section 4(j)
shall not apply to the Buyer’s Underlying Shares issued upon conversion of Shares in connection with an Anticipated Change
of Control Notice or a Forced Redemption Notice (in the latter case, solely with respect to Underlying Shares issued upon conversion
of the Shares that are the subject of such Forced Redemption Notice). The term “Underlying Shares” means, as
of any time of determination and with respect to any particular Shares, the shares of Common Stock then-issued plus the shares
of Common Stock then-remaining issuable upon conversion of such Shares in accordance with the terms of the Certificate of Designation.
Any Transfer by the Buyer (or any transferee of Shares held or formerly held by the Buyer) is subject to and conditioned upon the
intended recipient’s delivery to the Company of a written undertaking, in form and substance acceptable to the Company, pursuant
to which the intended recipient agrees to be bound by substantially the same restrictions as set forth in this Section 4(j).
Any purported Transfer of any Shares or Underlying Shares by the Buyer (or any transferee of Shares or Underlying Shares held or
formerly held by the Buyer) not made in compliance with the requirements of this Section 4(j) shall be null and void ab
initio, shall not be recorded on the books of the Company or its transfer agent and shall not be recognized by the Company.

 

(k)              
Notice of Disqualification Events. The Company will notify the Buyer in writing prior to each Closing of (i) any
Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a
Disqualification Event relating to any Issuer Covered Person.

 

 

 

 

    	 	20	 

     

    

 

(l)               
Compliance with Cannabis Law. The Company shall take all action to comply with state cannabis laws and regulations,
including making all requisite filings under such laws and regulations as and when required.

 

(m)             
Registration.

 

(i)               
After the earlier to occur of (1) a Listing Event (as defined in the Certificate of Designation), and (2) the date that
is 12 months after the Original Issue Date (as defined in the Certificate of Designation), if and for as long as the Buyer holds
Shares convertible into shares of Common Stock with a market value that is equal to at least $10,000,000 the Buyer shall have the
right to require the Company at any time, and from time to time, to file a registration statement on Form S-1 (or if eligible to
use Form S-3, a registration statement on Form S-3) with the SEC covering the resale of the Underlying Shares (each such registration
statement and each registration statement filed pursuant to Section 4(m)(ii), a “Resale Registration Statement”).

 

(ii)             
The Company also agrees that to the extent it files any registration statement with the SEC, other than a registration statement
on Form S-8, Form S-4 or Form S-3, it will prior to filing such registration statement, give the Buyer reasonable written notice
in order to permit the Buyer to include in such registration statement, the resale of the Underlying Shares; provided, however,
that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s)
thereof shall, in its reasonable discretion, impose a limitation on the number of Underlying Shares which may be included in such
registration statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary
to facilitate public distribution, then the Company shall be obligated to allocate for inclusion in such registration statement
the Underlying Shares of each participating holder of Underlying Shares in direct proportion (as nearly as practicable) to the
number of Underlying Shares requested to be included by such holder; provided, however, that the Buyer shall not be disproportionately
negatively affected as compared to other holders of Company securities to be registered.

 

(iii)           
The Company will promptly file and use best efforts to cause to become promptly effective such Resale Registration Statement
as well as any filings required under any applicable state securities laws or regulations. The Company shall keep such Resale Registration
Statement effective until the earlier of (1) such time as all of the Underlying Shares registered for resale under such Resale
Registration Statement have been sold pursuant to such Resale Registration Statement or otherwise, or (2) such time as the Underlying
Shares registered for resale under such Resale Registration Statement may be sold under Rule 144 without restriction or limitation
and without the requirement to be in compliance with Rule 144(c)(1). The Buyer’s right to demand registration of the Underlying
Shares shall not terminate until such time as all the Underlying Shares have been registered for resale with the SEC and the Buyer
has sold or otherwise transferred to Persons not affiliated with the Buyer all of such Underlying Shares. All costs related to
the preparation, filing and effectiveness of such registrations, including accounting and legal fees and expenses (including reasonable
fees and expenses of counsel for the Buyer) shall be borne by the Company. The Company will enter into an agreement with the Buyer
including customary terms and conditions for any such registration, including customary indemnification provisions.

 

(iv)            
Notwithstanding the foregoing obligations, the Company may, upon written notice to the Buyer, for a reasonable period of
time, not to exceed 45 days in the case of clauses (1) and (2) below, or 30 days in the case of clause (3) below (each, a “Suspension
Period”), delay the filing of a Resale Registration Statement or a request for acceleration of the effective date, or
suspend the effectiveness of any Resale Registration Statement, in the event that (1) the Company is engaged in any activity or
transaction or preparations or negotiations for any activity or transaction that the Company desires to keep confidential for business
reasons, if the Company’s board of directors determines in its reasonable good faith judgement that the public disclosure
requirements imposed on the Company under the Securities Act in connection with the Resale Registration Statement would require
at that time disclosure of such activity, transaction, preparations or negotiations and such disclosure could result in material
harm to the Company or its business transactions or activities, (2) the Company does not yet have appropriate financial statements
of any acquired or to be acquired entities necessary for filing, or (3) any other event occurs that makes any statement of a material
fact made in such Resale Registration Statement, including any document incorporated by reference therein, untrue or that requires
the making of any additions or changes in the Resale Registration Statement in order to make the statements therein not misleading.
The Company may not invoke its right to suspend or delay a registration statement pursuant to this Section 4(m)(iv) more than twice
in any twelve month period. If the Company suspends the effectiveness of a Resale Registration Statement pursuant to this Section
4(m)(iv), the Company shall, as promptly as reasonably practicable following the termination of the circumstance which entitled
the Company to do so, take such actions as may be necessary to reinstate the effectiveness of such Resale Registration Statement
and give written notice to the Buyer authorizing the Buyer to resume offerings and sales pursuant to such Resale Registration Statement.

 

 

 

    	 	21	 

     

    

 

(v)             
It shall be a condition precedent to the obligations of the Company to file or effect any Resale Registration Statement
pursuant to this Section 4(m) that the Buyer shall furnish to the Company such information regarding itself, the Company securities
held by it and the intended method of disposition of the Underlying Shares held by it as shall be reasonably required to effect
and maintain the effectiveness of the registration of such Resale Registration Statement and shall execute such documents in connection
with such registration as the Company may reasonably request.

 

(vi)            
Notwithstanding anything contained herein to the contrary, the Company shall not be obligated to (1) effect a registration
pursuant to this Section 4(m) within 90 days after the effective date of a previous registration; (2) effect a registration pursuant
to this Section 4(m) unless the request is for a number of shares of Common Stock with a market value that is equal to at least
$3,000,000 as of the date of such request; (3) effect a registration if the Company has effected two registrations on a Resale
Registration Statement in the 12-month period prior to such request, or (4) file or effect a Resale Registration Statement with
respect to any Underlying Shares subject to a registration demand that may be sold under Rule 144 without restriction or limitation
and without the requirement to be in compliance with Rule 144(c)(1) limitation.

 

(n)              
Closing Documents. On or prior to 14 calendar days after each Closing, the Company agrees to deliver, or cause to
be delivered, to the Buyer a complete closing set of the executed Transaction Documents and any other documents required to be
delivered to any party hereto pursuant to Section 6 hereof or otherwise.

 

(o)              
Equity Incentive Plan Limitation. For as long as the Buyer holds Shares, without the prior written consent of the
holders of at least a majority of the then-outstanding shares of Preferred Stock, the Company shall not have issued and outstanding
awards under any equity incentive plan for the issuance of shares of Common Stock representing more than 12% of the then-issued
and outstanding shares of Common Stock (calculated on an as-converted, fully-diluted basis, excluding warrants) in the aggregate.

 

(p)              
Regulation M. The Company will not take any action prohibited by Regulation M under the 1934 Act, in connection with
the distribution of the Securities contemplated hereby.

 

(q)              
General Solicitation. None of the Company, any of its affiliates (as defined in Rule 501(b) under the 1933 Act) or
any person acting on behalf of the Company or such affiliate will solicit any offer to buy or offer or sell the Preferred Stock
by means of any form of general solicitation or general advertising within the meaning of Regulation D, including: (i) any advertisement,
article, notice or other communication published in any newspaper, magazine or similar medium or broadcast over television or radio;
and (ii) any seminar or meeting whose attendees have been invited by any general solicitation or general advertising.

 

(r)               
Integration. None of the Company, any of its affiliates (as defined in Rule 501(b) under the 1933 Act), or any person
acting on behalf of the Company or such affiliate will sell, offer for sale, or solicit offers to buy or otherwise negotiate in
respect of any security (as defined in the 1933 Act) which will be integrated with the sale of the Securities in a manner which
would require the registration of the Securities under the 1933 Act or require stockholder approval under the rules and regulations
of the Principal Market and the Company will take all action that is appropriate or necessary to assure that its offerings of other
securities will not be integrated for purposes of the 1933 Act or the rules and regulations of the Principal Market, with the issuance
of Securities contemplated hereby.

 

 

 

 

    	 	22	 

     

    

 

5.                 
CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

 

(a)              
The obligation of the Company hereunder to issue and sell the Shares to the Buyer at each Closing is subject to the satisfaction,
at or before such Closing, of each of the following conditions, provided that these conditions are for the Company’s sole
benefit and may be waived by the Company at any time in its sole discretion by providing the Buyer with prior written notice thereof:

 

(i)              
The Buyer shall have executed each of the Transaction Documents to which it is a party and delivered the same to the Company.

 

(ii)            
The Buyer shall have delivered to the Company the Buyer’s aggregate Purchase Price, for the Shares being purchased
by the Buyer at such Closing by wire transfer of immediately available funds pursuant to the wire instructions provided by the
Company.

 

(iii)           
The representations and warranties of the Buyer shall be true and correct as of the date when made and as of such Closing
as though made at that time (except for representations and warranties that speak as of a specific date which shall be true and
correct as of such specified date), and the Buyer shall have performed, satisfied and complied in all material respects with the
covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Buyer at or
prior to such Closing.

 

6.                 
CONDITIONS TO THE BUYER’S OBLIGATION TO PURCHASE.

 

(a)              
The obligation of the Buyer hereunder to purchase the Shares that the Buyer is purchasing at each Closing is subject to
the satisfaction, at or before such Closing, of each of the following conditions, provided that these conditions are for the Buyer’s
sole benefit and may be waived by the Buyer at any time in its sole discretion by providing the Company with prior written notice
thereof:

 

(i)              
The Company shall have duly executed and delivered to the Buyer (A) each of the Transaction Documents, and (B) the Shares
being purchased by the Buyer at such Closing pursuant to this Agreement.

 

(ii)             
The representations and warranties of the Company shall be true and correct as of the date when made and as of such Closing
as though made at that time (except for representations and warranties that speak as of a specific date which shall be true and
correct as of such specified date) and the Company shall have performed, satisfied and complied in all material respects with the
covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company
at or prior to such Closing. The Buyer shall have received a certificate, executed by an officer of the Company, dated as of such
Closing, to the foregoing effect and as to such other matters as may be reasonably requested by the Buyer in the form attached
hereto as Exhibit A.

 

(iii)           
The Common Stock (I) shall be designated for quotation on the Principal Market and (II) shall not have been suspended, as
of such Closing, by the SEC or the Principal Market from trading on the Principal Market nor shall suspension by the SEC or the
Principal Market have been threatened, as of such Closing, either (A) in writing by the SEC or the Principal Market or (B) by falling
below the minimum listing maintenance requirements of the Principal Market.

 

(iv)            
The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for
the sale of the Shares and the consummation of the transactions contemplated hereby.

 

 

 

 

 

    	 	23	 

     

    

 

(v)             
The Company shall have delivered to the Buyer such other documents relating to the transactions contemplated by this Agreement
as the Buyer or its counsel may reasonably request.

 

(vi)            
The Company shall have raised or otherwise secured a minimum of $31,520,000 of capital from any combination of the sale
of shares of Preferred Stock and proceeds to be disbursed to the Company from a loan under a credit facility evidenced by a commitment
to lend (provided that such commitment may be subject to draw on the credit facility and may be funded in tranches; exclusive of
original issue discount on the loan).

 

7.                 
MISCELLANEOUS.

 

(a)              
Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of Nevada, without giving effect to any choice of law or
conflict of law provision or rule (whether of the State of Nevada or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of Nevada. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is
improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY
RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH
OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

(b)              
Counterparts. This Agreement may be executed in two or more counterparts, all of which shall be considered one and
the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party;
provided that a facsimile or .pdf signature shall be considered due execution and shall be binding upon the signatory thereto with
the same force and effect as if the signature were an original, not a facsimile or .pdf signature.

 

(c)              
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement.

 

(d)              
Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed
amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified
continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited
nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations
or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the
parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s)
with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

 

 

 

    	 	24	 

     

    

 

(e)              
Entire Agreement; Amendments. This Agreement and the other Transaction Documents supersede all other prior oral or
written agreements between the Buyer, the Company, their affiliates and Persons acting on their behalf with respect to the matters
discussed herein, and this Agreement, the other Transaction Documents and the instruments referenced herein and therein contain
the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set
forth herein or therein, neither the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect
to such matters. No provision of this Agreement may be amended or waived other than by an instrument in writing signed by
the Company and the Buyer, and any amendment or waiver to this Agreement made in conformity with the provisions of this Section 7(e)
shall be binding on all holders of Securities and the Company. No such amendment shall be effective to the extent that it
applies to less than all of the holders of the applicable Securities then outstanding. No consideration shall be offered or
paid to any Person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents unless
the same consideration (other than the reimbursement of legal fees) also is offered to all of the parties to the Transaction Documents;
provided, however, for clarity, any Person’s participation in a subsequent securities offering of the Company shall not be
consideration for this purpose. The Company has not, directly or indirectly, made any agreements with the Buyer relating to the
terms or conditions of the transactions contemplated by the Transaction Documents except as set forth in the Transaction Documents.
Without limiting the foregoing, the Company confirms that, except as set forth in this Agreement, the Buyer has not made any commitment
or promise or has any other obligation to provide any financing to the Company or otherwise. Whenever this Agreement requires the
consent or approval of the holders of the Preferred Stock, unless otherwise expressly and specifically set forth in this Agreement,
such consent or approval shall require the approval of the Buyer.

 

(f)               
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms
of this Agreement or any of the other Transaction Documents must be in writing and will be deemed to have been delivered: (i) upon
receipt, when delivered personally; (ii) upon delivery, when sent by facsimile (provided confirmation of transmission is mechanically
or electronically generated and kept on file by the sending party) or by electronic mail; (iii) upon delivery, when sent by electronic
mail (provided that the sending party does not receive an automated rejection notice); or (iv) upon receipt, when sent by overnight
courier service, in each case properly addressed to the party to receive the same. The addresses, facsimile numbers and e-mail
addresses for such communications shall be:

 

If to the Company:

 

Medicine Man Technologies, Inc.

4880 Havana Street, Suite 201

Denver, CO 80239

Telephone:       (303)
371-0387

Facsimile:        (303)
371-0598

Attention:         General
Counsel

E-mail:             dan@schwazze.com

 

If to the Buyer, to the Buyer’s address
and e-mail address set forth on the signature page hereto, with copies to the Buyer’s representatives as set forth on its
signature page hereto. Any notice address, facsimile number or email address for a party may be changed by delivering such other
address, facsimile number and/or e-mail address and/or to the attention of such other Person as the specified by written notice
given to the Company or the Buyer, as applicable, five calendar days prior to the effectiveness of such change. Written confirmation
of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically
generated by the sender’s facsimile machine or e-mail containing the time, date, recipient facsimile number and an image
of the first page of such transmission or (C) provided by an overnight courier service shall be rebuttable evidence of personal
service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above,
respectively.

 

 

 

 

    	 	25	 

     

    

 

(g)              
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written
consent of the Buyer. The Buyer shall not assign this Agreement or any rights or obligations hereunder without the prior written
consent of the Company.

 

(h)              
No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective
permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

(i)                
Survival. Unless this Agreement is terminated by mutual written agreement between the Company and the Buyer, the
covenants and agreements of the Company and the Buyer shall survive each Closing. The representations and warranties of the Company
and the Buyer shall survive each Closing until the two-year anniversary thereof.

 

(j)                
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and
things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may
reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

(k)              
Indemnification.

 

(i)                
In consideration of the Buyer’s execution and delivery of the Transaction Documents and acquiring the Securities thereunder
and in addition to all of the Company’s other obligations under the Transaction Documents, the Company shall defend, protect,
indemnify and hold harmless the Buyer and its stockholders, partners, members, officers, directors, employees and direct or indirect
investors and any of the foregoing Persons’ agents or other representatives (including, without limitation, those retained
in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”) from and
against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, other than
special, exemplary, incidental, punitive or consequential damages, including lost profits, diminution in value, damage to reputation
or the like unless any such damages are awarded to a third party, and expenses in connection therewith (irrespective of whether
any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’
fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising
out of, or relating to (x) any misrepresentation or breach of any representation or warranty made by the Company or any Subsidiary
in this Agreement, or (y) any breach of any covenant, agreement or obligation of the Company or any Subsidiary contained in this
Agreement or (z) any untrue or alleged untrue statement of a material fact contained in any Resale Registration Statement or any
amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or
necessary to make the statements therein not misleading; provided, however, that the Company will not be liable in any such case
to the extent that any such Indemnified Liabilities (A) arise primarily out of or is based primarily upon the inaccuracy of any
representations and warranties made by the Buyer in this Agreement or (B) are caused by or contained in any information furnished
in writing to the Company by the Buyer expressly for use in a Resale Registration Statement or any amendment thereof or supplement
thereto. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make
the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable
law. Notwithstanding anything to the contrary herein, the Company’s aggregate liability under this Section 7(k) to any Indemnitee
shall not exceed the Purchase Price paid by the Buyer.

 

 

 

 

 

 

    	 	26	 

     

    

 

(ii)             
Promptly after receipt by an Indemnitee under this Section 7(k) of notice of the commencement of any action or proceeding
(including, without limitation, any governmental action or proceeding) involving an Indemnified Liability, such Indemnitee shall,
if a claim in respect thereof is to be made against any indemnifying party under this Section 7(k), deliver to the indemnifying
party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to
the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of
the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnitee; provided, however, that an
Indemnitee shall have the right to retain its own counsel with the fees and expenses of such counsel to be paid by the indemnifying
party if: (x) the indemnifying party has agreed in writing to pay such fees and expenses; (y) the indemnifying party shall have
failed promptly to assume the defense of such Indemnified Liability and to employ counsel reasonably satisfactory to such Indemnitee
in any such Indemnified Liability; or (z) the named parties to any such Indemnified Liability (including, without limitation, any
impleaded parties) include both such Indemnitee and the indemnifying party, and such Indemnitee shall have been advised by counsel
that a conflict of interest is likely to exist if the same counsel were to represent such Indemnitee and the indemnifying party
(in which case, if such Indemnitee notifies the indemnifying party in writing that it elects to employ separate counsel at the
expense of the indemnifying party, then the indemnifying party shall not have the right to assume the defense thereof and such
counsel shall be at the expense of the indemnifying party), provided further that in the case of clause (z) above the indemnifying
party shall not be responsible for the reasonable fees and expenses of more than one (1) separate legal counsel for such Indemnitee.
The Indemnitee shall reasonably cooperate with the indemnifying party in connection with any negotiation or defense of any such
action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the
Indemnitee which relates to such Indemnified Liability. The indemnifying party shall keep the Indemnitee reasonably apprised at
all times as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable
for any settlement of any action, claim or proceeding effected without its prior written consent; provided, however, the indemnifying
party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the prior written consent
of the Indemnitee, consent to entry of any judgment or enter into any settlement or other compromise which does not include as
an unconditional term thereof the giving by the claimant or plaintiff to such Indemnitee of a release from all liability in respect
to such Indemnified Liability, and such settlement shall not include any admission as to fault on the part of the Indemnitee. Following
indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnitee with respect
to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver
written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such
indemnifying party of any liability to the Indemnitee under this Section 7(k), except to the extent that the indemnifying party
is materially and adversely prejudiced in its ability to defend such action. The indemnity agreements contained herein shall be
in addition to (A) any cause of action or similar right of the Indemnitees against the indemnifying party or others, and (B) any
liabilities the indemnifying party may be subject to pursuant to the law.

 

(l)                
Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party. Each party hereto agrees that
such party and/or its legal counsel has reviewed and had an opportunity to revise the Transaction Documents and, therefore, the
normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed
in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices
and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock
dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.

 

(m)            
Remedies. The Buyer and each holder of the Securities shall have all rights and remedies set forth in the Transaction
Documents and all rights and remedies which such holders have been granted at any time under any other agreement or contract and
all of the rights which such holders have under any law. Any Person having any rights under any provision of this Agreement shall
be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any
breach of any provision of this Agreement and to exercise all other rights granted by law. Furthermore, the Company recognizes
that in the event that it fails to perform, observe, or discharge any or all of its obligations under the Transaction Documents,
any remedy at law may prove to be inadequate relief to the Buyer. The Company therefore agrees that the Buyer shall be entitled
to seek temporary and permanent injunctive relief in any such case without the necessity of proving actual damages and without
posting a bond or other security. The remedies provided in this Agreement and the other Transaction Documents shall be cumulative
and in addition to all other remedies available under this Agreement and the other Transaction Documents, at law or in equity (including
a decree of specific performance and/or other injunctive relief).

 

 

 

    	 	27	 

     

    

 

(n)              
Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) this Agreement, whenever the Buyer exercises a right, election, demand or option under this Agreement and the Company or any
Subsidiary does not timely perform its related obligations within the periods therein provided, then the Buyer may rescind or withdraw,
in its sole discretion from time to time upon written notice to the Company or such Subsidiary (as the case may be), any relevant
notice, demand or election in whole or in part without prejudice to its future actions and rights.

 

(o)              
Payment Set Aside. To the extent that the Company makes a payment or payments to the Buyer hereunder or pursuant
to any of the other Transaction Documents or the Buyer enforces or exercises its rights hereunder or thereunder, and such payment
or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent
or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company,
a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, foreign, state or federal
law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally
intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement
or setoff had not occurred.

 

(p)              
Enforcement Fees. The prevailing party in any dispute under or relating to this Agreement shall have the right to
collect from the other all costs and expenses incurred by such prevailing party as a result of enforcement of this Agreement and
the collection of any amounts owed to such prevailing party hereunder (whether in cash, equity or otherwise), including, without
limitation, reasonable attorneys’ fees and expenses.

 

[Signature Page(s) Follows]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	28	 

     

    

 

IN WITNESS WHEREOF,
the Buyer and the Company have caused their respective signature page to this Securities Purchase Agreement to be duly executed
as of the date first written above.

 

	 	COMPANY:
	 	 	 
	 	MEDICINE MAN TECHNOLOGIES, INC.
	 	 	 
	 	By:	/s/Justin Dye
	 	 	Name: Justin Dye
	 	 	Title: Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	29	 

     

    

 

IN WITNESS WHEREOF,
the Buyer and the Company have caused their respective signature page to this Securities Purchase Agreement to be duly executed
as of the date first written above.

 

	 	BUYER:
	 	 	 
	 	CRW CAPITAL CANN HOLDINGS, LLC
	 	 	 
	 	 	 
	 	 	 
	 	By:	/s/ Jeff Cozad
	 	 	Name: Jeff Cozad
	 	 	
        Title: President

        Address:

        4740 W. Mockingbird Lane

        PO Box #195579

        Dallas, TX 75209

 

 

	 	 
	 	Copies of notices to:
	 	 
	 	 
	 	Attention: Marc Rubin
	 	Email: marc@revitycapital.com

 

 

 

 

    	 	30	 

     

    

 

EXHIBIT A

 

FORM OF OFFICER’S CERTIFICATE

 

(See attached.)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]